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Abstract
Magnetic Particle Imaging (MPI), a novel imaging technology, offers hotspot visualization and
quantification of superparamagnetic iron oxide (SPIO) labelled cells in vivo. Bioluminescence
imaging (BLI), with the sensitive reporter Akaluc, can provide complementary information on
cell viability and proliferation. Here, we combined MPI, and Akaluc BLI for a more holistic
picture of cancer cell fate in mice. Breast cancer cells labelled with Akaluc and the SPIO
Synomag-D, were injected into the mammary fat pad (MFP) of mice and imaged on BLI and
MPI for 2-weeks. Over this period, BLI signal increased due to tumour progression, while MPI
signal decreased due to probe dilution in proliferating cells. Both modalities detected metastases,
however, they were visualized in different locations. Overall, Akaluc BLI complemented MPI,
providing sensitive detection of distant metastases, and longitudinal measures of cell viability.
This multimodal approach should improve our understanding of metastasis, and aid development
of novel therapeutics.

Keywords
Magnetic Particle Imaging (MPI), Superparamagnetic Iron Oxide (SPIO), Synomag-D,
Bioluminescence Imaging (BLI), Akaluc, Akalumine-HCl, Multimodal imaging, Cancer cell
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Summary for Lay Audience
The purpose of this thesis is to combine two imaging tools to help visualize cancer cells injected
into mice. Magnetic particle imaging or MPI, is a new imaging system which can directly detect
and quantify iron particles. Cells can be labelled with these iron particles and tracked throughout
the body. However, when cells divide, the amount of iron within each cell gets diluted, and may
get dispersed throughout the body. Additionally, dead cells will continue to produce a signal. For
these reasons MPI cannot be used to study cell proliferation or viability. We believe that
bioluminescence imaging or BLI would nicely complement MPI as it can be used to measure
both proliferation and viability over long durations. One major limitation of BLI however, is that
the light used in BLI gets absorbed by various tissues, reducing the signal which can be detected.
This makes it very difficult to see areas deep inside the body. A solution to this is to use a
reporter which produces near infrared light (NIR), as it is absorbed in lower amounts than visible
light. Recently the BLI reporter Akalumine was developed, which when in contact with the
enzyme Akaluc, produces NIR light. This project combines MPI with Akaluc BLI to track cancer
cells injected into mice. Described in chapter 2, breast cancer cells were labelled with both iron
particles and Akaluc, and then injected into mice. Following this, MPI and BLI scans were taken
for 2-weeks. MPI and BLI signals were compared to determine the strengths and limitations of
each, as well as to determine how they complemented each other. Chapter 3 highlights the
limitations of this work, and the future directions of this project.
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Chapter 1
This chapter will serve to provide all necessary background information pertinent to this thesis. Topics
covered include breast cancer, probe-based cellular imaging, and reporter gene cellular imaging.
Findings from relevant literature will also be discussed.

1.1 General Introduction
This thesis explores the development of a multimodality imaging strategy to monitor the fate of
orthotopically implanted breast cancer cells in a mouse model. Specifically, we are exploring the
combination of bioluminescence imaging (BLI) with a highly sensitive and relatively new BLI reporter
gene called Akaluc, with magnetic particle imaging (MPI) which images iron oxide nanoparticles that
can be loaded into cancer cells prior to implantation.

1.1.1 Breast Cancer
Breast cancer is one of the most common cancer diagnoses for women, accounting for a quarter of all
new female cancer cases (1). Due in part to the high prevalence, breast cancer has proven to be one of
the deadliest diseases facing Canadian women. The Canadian Cancer Society estimates that for
Canadian Women, an incredible 1 in every 33 deaths can be attributed to breast cancer (2,3). This
makes it the second leading cause of death for this population. The mortality rate associated with
breast cancer is highly dependent on which stage the cancer is detected at. Breast cancer diagnosed in
stage one or two has a 5-year survival rate of 100%, however if the cancer is not detected until stage 4,
the 5-year survival rate drops to only 22% (2). This large discrepancy in survival is due to the dangers
associated with breast cancer metastasis. It is estimated that at least 2/3 of breast cancer deaths are
associated with cell metastasis (4). This is the process where cells migrate from a primary tumor site
and form secondary lesions in disperse tissues such as bone, lung, brain, liver, and lymph nodes (5).
Cancer in these locations poses a great risk to patient health, with metastatic breast cancer being
generally classified as an “incurable disease” at this time (6).
While there are many variations in breast cancer treatment, depending on the staging, and the
presented biomarkers, the most common approach involves surgery possibly in combination with
radiation and/or drug therapies (7). Invasive surgeries are used to excise the primary tumor while
systemic approaches such as radiation and drug therapies treat possible micrometastaes (7). Breast
cancer, however, is a heterogenous disease (8). The same treatment may not have the same efficacy in
different patients. As it stands, the death rate for late-stage breast cancer patients remains staggeringly

2
high (2). Combining this with the invasiveness of both surgery and radiation, leaves a need for new
and more effective treatment methods, better suited to treat breast cancer patients as a whole. Efforts
have been made to develop new cell-based treatments such as CAR-T cell therapy (9-13), and NK cell
therapy (14,15). To properly assess the efficacy of these treatments preclinical models must be
implemented.

1.1.2 Preclinical Models of Breast Cancer
Preclinical models have long been implemented in the field of cancer research, providing unique tools
that would be otherwise inaccessible to researchers and health care professionals (16). Preclinical
models for cancer can date their origin back to Clarence Cook Little’s inbred mice strains in the early
1900s (17), as well as the HeLa cancer cell line taken form the cervix of Henrietta Lacks in 1951 (18).
Today, there are several preclinical models which can and have been used for breast cancer research,
including zebrafish (19,20), drosophila (21,22), and pigs (23,24), however, cell lines and mouse
models remain the most widespread (16,25).
Preclinical animal models have seen extensive use in research, especially within the last few decades,
as they provide invaluable information to the researchers using them. The use of preclinical models
reduces the risk to patients while allowing researchers to alter variables that they otherwise wouldn’t
be able to control. Animal models for breast cancer provide insight into (i) the biological mechanisms
of disease progression, including primary tumor development, molecular markers, and metastasis (2631), (ii) the development of novel treatments and therapeutic agents (32-36), (iii) the efficacy of
combined treatment regiments (37-41), (iv) the development of new diagnostic imaging modalities,
tracers, and methods (42-46), and (v) the role of natural protection and the immune system in cancer
prevention (47-51). To better evaluate these animals over time, it would be valuable to track cancer
cells noninvasively with imaging.

1.2 Cellular Imaging
Being able to visualize, localize, and quantify cells noninvasively is critical for gaining a better
understanding of cellular processes such as cancer progression and metastasis. By improving cell
tracking for cancer cells, researchers hope to gain a better understanding of the underlying mechanisms
of cancer, and to evaluate the effectiveness of new treatments, which may expedite their translation
into the clinic. In addition, with the clinical adaptation and continued development of cellular
therapies, sensitive methods for tracking therapeutic cells to better understand treatment efficacy in
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real time are needed. Researchers have implemented various imaging modalities for cell tracking over
the years. These include optical imaging such as fluorescence imaging (FLI) and BLI, as well as
modalities highly used in the clinic such as ultrasound, positron-emission tomography (PET), single
photon-emission computed tomography (SPECT), and magnetic resonance imaging (MRI). Two main
strategies for tracking cells with these modalities are probe-based cell tracking through direct labelling,
and reporter gene imaging, via indirect labelling (52-54). Below, we define these tracking and labelling
methods, as well as highlight the strengths and limitations for each strategy. Additionally, cells can be
labelled in situ, which while not used in this thesis, is described in section 2.3.

1.2.1 Probe-Based Cell Tracking (Direct Labeling)
A common way to track cells is to ex vivo label the cells in culture with imaging probes prior to
injection into the subject of interest and imaging (55,56). Probe based imaging is a fairly simple
method, as it doesn’t involve genetic modifications. When comparing labelling methods for the same
imaging modality, direct labelling is typically more sensitive than indirect labelling. Probe-based MRI
has repeatedly shown the ability to track single cells in vivo (57-62), while MRI using reporter genes
has consistently reported sensitivity as one of the primary limitations (63-67). It is important to note
however, that some reporter gene imaging modalities, such as BLI, have shown incredible sensitivity.
This will be further described in section 1.2.2.
While highly sensitive, there are a few limitations common to all probe-based imaging techniques.
First, the label may be diluted, or passed asymmetrically to daughter cells during cell division. This
prevents the indefinite imaging of dividing cell populations; however non-proliferative cells can be
imaged over longer durations. (59-60,68,69). Additionally, the tracer may be expelled when cells die,
continuing to produce an imaging signal outside the cell, which may give false positive results of
where the cells are located (70). If scavenger cells, such as macrophages, engulf these, a false positive
signal may also be observed in distal clearance organs (70). These limitations can be seen in Figure
1.1. below.
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Figure 1.1:
A.

B.

C.

Figure 1.1. Common limitations of probe-based imaging. While highly sensitive, probe-based
imaging techniques share some common limitations based on their labelling method. (A) The
concentration of tracer (represented by “Fe” within red circles) in cells is diluted upon cell division, and
daughter cells may receive unequal amounts of said tracer. This makes quantification of cells for
proliferative populations difficult. (B) As cells die, iron remains in the vicinity, causing false positive
signals. This prevents the visualization of viability. (C) This remaining iron may be engulfed by
bystander cells such as macrophages. This results in signal clearance and may cause erroneous signal in
distant locations. Figure made in BioRender.
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Iron-Based Cell Tracking with MRI
MRI has quickly established itself as one of the most popular cell tracking modalities due to its high
spatial resolution and soft-tissue contrast, making it easy to discern transplanted cells from background
tissue (71,72). Additionally, due to its prevalence, cell tracking methods using MRI have been refined
and improved over the last few decades. Standard protocols have been thoroughly developed making
MRI easy to use. The most common way MRI is used to track cells is to label them with either
paramagnetic, or superparamagnetic 1H-MRI contrast agents, sometimes with the help of transfection
agents, as first described by Tzu-Chen et al, and Bulte & Brooks in the 90s (73,74).
Paramagnetic agents are typically composed of either Gadolinium, or Manganese (75-77). These
agents shorten the longitudinal relaxation rate, T1, by increasing the relaxivity of water protons (7779). This creates a positive contrast, which has been used previously by researchers to detect and track
early lung metastasis in a mouse breast cancer model (80), as well as characterizing the early growth of
prostate tumors (81). Paramagnetic contrast agents, while useful given their positive contrast, are
limited by their relatively low sensitivity, limiting the number of cells that can be detected (82-84).
Superparamagnetic contrast agents, by definition, offer higher sensitivity than paramagnetic agents
(82-84). These agents consist of iron oxide particles coated in a biologically inert material such as
dextran or carboxydextran (Superparamagnetic iron oxide particles: SPIOs) (85,86). Iron based
contrast agents are the main agents used in T2/T2* weighted MRI sequences (87,88). Iron particles
effect T2* relaxation, causing local disturbances in the magnetic field (87,88). This results in a dark
signal void, surrounding the areas where the iron is present. The large void associated with iron-based
MRI is what’s known as a ‘blooming artifact” (89). An illustration of this can be seen in Figure 1.2. As
the signal void created is large in comparison to the iron tracer, this imaging method has
characteristically high sensitivity, but lower spatial resolution (90).
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Figure 1.2:

Figure 1.2 Schematic of signal voids associated with T2 MRI of superparamagnetic contrast
agents. MRI of superparamagnetic iron oxide (SPIO) contrast agents, denoted as “Fe” in this image,
results in a blooming artifact (grey circles). These blooming artifacts far exceed the diameter of the SPIO
tracer resulting in higher sensitivity but severely reduced resolution. Figure made in BioRender.
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There are two main strategies for labelling cells with iron oxide particles. The first method involves
intravenous injection of the iron nanoparticle where it is taken up by cells within the animal model in
situ (91,92). This method is often done to study clearance and biodistribution of a nanoparticle (93-95),
to load scavenger cells such as macrophages (91,92,96-98), or in experiments reliant on the enhanced
permeability and retention effect (EPR) for tracer accumulation in cancerous tissues (99-101). The
second method involves loading cells with the iron tracer prior to injection. This can be accomplished
by incubating the cells with the tracer, which takes up the iron through endocytosis. Iron loading can
be aided by transfection agents such as protamine sulphate and heparin (102-104), as was done in this
project.
SPIOs have quickly emerged as the preferred probe for cell tracking. Bulte and Kraitchman believe
this preference is due to a multitude of factors including (i) having higher signal change per iron
content, (ii) containing biocompatible iron which can be metabolized by the cell, and (iii) coating on
their surface can be easily functionalized (105). Cells can be labelled with superparamagnetic contrast
agents such as SPIOs through coincubation resulting in endocytosis. These iron containing cells can be
indirectly detected with MRI via the blooming artifact (89). Various cell types have been tracked with
iron-based MRI thus far including stem cells (57,106-108), immune cells (62,109-113), and most
importantly for this thesis cancer cells (59,60,69,114-116).
While stem and immune cells remain popular cell types for tracking, due to their emergence in various
clinical therapies, iron-based cancer cell tracking remains less common. This scarcity is driven by the
difficulties imaging cancer cells over long periods (68). Cancer cells are highly proliferative, resulting
in dilution of the iron tracer for each cell passage. Several groups have examined this quality in vitro.
Foster et al., reported in 2008 that intracellular iron loaded into B16F10 proliferative melanoma cells
was absent 5 days, or 6 generations post loading (60). Similarly, Econompolous et al., noticed that by
day 4, over half of their iron-loaded MDA-MB-231 cells had undetectable levels of iron. By day 10,
this percent dropped to only 1%. These findings indicate that signal would not be detectable using
MRI, limiting MRI cell tracking to short durations for cancer cell tracking (69). This finding only
holds true for proliferative cancer cell populations. Heyn et al., demonstrated that subpopulations of
“non-proliferative” quiescent MDA-MB-231 breast cancer cells retained the iron oxide tracer for
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upwards of a month in vivo (59). Similar findings were also found for SPIO labelled melanoma cells
(115) and in metastatic lymph nodes (69).
One use for cancer cell tracking which has been exploited by researchers is the study of cell migration
and metastasis. Econompolous et al., were the first group to visualize cancer regions outside of the
primary tumor usen iron-based imaging. Iron loaded MDA-MB-231 cells, originally injected into the
mammary fat pad of mice, were found on day 14 in the axillary and inguinal lymph nodes (69).
Recently, researchers in our lab have applied the effects of superparamagnetic contrast agents on the
T2 relaxation to visualize breast cancer metastasis to the brain of nude mice (117). Additionally,
micron sized superparamagnetic iron particles (MPIO) have been used to monitor the fate of
transplanted gastric cancer cells and track the migration of metastatic cells through the lymphatic
system, by the Guo lab (118). Utilizing the blooming effect associated with iron based-MRI cell
tracking, Heyn et al., were able to determine the fate of single breast cancer cells which had
metastasized to the brain (58,59). Single cancer cells were also detected by Foster et al., and Shapiro et
al., This finding demonstrates the incredible sensitivity possible with probe-based cell tracking
methods such as MRI (60-62).
With both paramagnetic and superparamagnetic contrast agents, researchers have often questioned the
deleterious effects of these particles on cell function, viability, and protein expression. Although most
studies have shown little significant effect on loaded cells (119), one study published in Neuroimage
showed Gadolinium having a non-zero effect on cellular repair mechanisms in a transplanted neural
stem cells over a 1-year period (120). Other studies have linked SPIO loading to cellular stress (121125), decreased gene expression and gene silencing (126-128), and cell proliferation (122,129,130).
While MRI using SPIO continues to be one of the most widely utilized modalities for cell tracking,
major drawbacks limit the applications of this modality. Although, the SNR between dark signal voids
and lighter background tissue may be high, dark regions are harder to visually discern making it
suboptimal. Additionally, air filled tissues such as lungs appear black in T2 weighted MRI. As this is
one of the most common locations for breast cancer metastasis (5), it makes tracking the full scope of
metastasis difficult. Since these iron particles are indirectly detected, quantification of cells becomes
difficult, as the signal intensity will not change linearly with iron content (86,131-133). Although
efforts have been made to quantify MRI signal (134-137), cell numbers are often estimated by
comparing the size of the signal void to cell number. Magnetic particle imaging (MPI) is a new
modality that can help overcome some of these issues with MRI based cell tracking with SPIO agents.
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Magnetic Particle Imaging (MPI)
Magnetic Particle Imaging (MPI) is a novel imaging modality first conceptualized by Bernhard Gleich
in 2001 (138). The concept was further expanded upon in the ground-breaking 2005 Nature paper by
Gleich and Jurgen Weizenecker, a colleague with the Phillips Research team in Hamburg Germany
(139). Within this paper, the first ever images were generated using the principles of MPI. These
images consisted of undiluted samples of Vivotrax (which also goes by the names Resovist and
Ferucarbotran), a commercially available MRI contrast agent (140). While limited to preliminary in
vitro data, this work effectively demonstrated the feasibility of MPI as an imaging modality,
welcoming researchers from around the world to improve upon the technology and its applications
(139).
While the name shares striking similarities to Magnetic Resonance Imaging, MPI and MRI are not the
same thing. The physics underlying MPI sets it apart from other imaging modalities, leading to its
unique imaging characteristics. MPI utilizes two strong electromagnets, set up opposite one another.
Similar to when bar magnets are placed in opposition, the generated magnetic field is cancelled out in
the middle creating a “Field Free Region” (FFR) (42,133,139, 141-144). The schematic for this
hardware setup can be seen in Figure 1.3.
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Figure 1.3:

Figure 1.3. Schematic of MPI magnetic fields. MPI uses two electromagnets opposite one another, in
inverse orientation. The magnets generate electromagnetic fields, as represented by the arrows. Where
these fields cancel out in the middle, a field free region is formed (FFR), as highlighted by the red circle.
Figure made in BioRender.
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The FFR can be moved in three dimensions over the entire image view. Mechanical changes such as
moving the bed in and out of the bore, and rotating the gantry are responsible for two of the
dimensions. Additionally, by changing the current, the strength of each main magnet can be altered,
shifting the field free region in the third dimension (145). The location of this FFR plays a critical role
in generating signal from the MPI tracer. When the FFR passes over superparamagnetic iron, the
magnetization of the iron flips resulting in a Voltage drop and corresponding signal. This drop in
voltage in the receiver coil is turned into signal. (133,141-145). As described above in section 2.1.1,
the use of SPIOs, such as Vivotrax in medical imaging is not a new development, however, MPI acts
as the first system to use nanoparticles as the core tracer (146,147). SPIO were previously used as MRI
contrast agents but repurposed to serve as tracers for MPI taking advantage of their unique behaviours
in oscillating magnetic fields (146,147).
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Figure 1.4:
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Figure 1.4. Schematic for the Behaviour of SPIO in Magnetic Fields for MPI. When in the presence
of a magnetic field, SPIO (red arrows) will align with the field. Depending on the position of the SPIO
with respect to the magnetic fields, this can result in negative saturation (i), or positive saturation (iii).
When in the field free region, SPIO are randomly aligned, and have no net magnetization (ii). As the
FFR passes over SPIO, their saturation will flip from negative to positive, as plotted by the Langevin
function in (B), where M is magnetization and H is the applied magnetic field. The derivative of this
curve gives a point spread function (PSF) shown in cyan. This PSF is the generated signal in MPI. Figure
made in BioRender.
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The specific choice in SPIO has a great effect on the sensitivity and resolution of an image (148).
SPIOs consist of a Fe3O4 and/or Fe2O3 magnetic core, coated in a biocompatible layer such as dextran.
Characteristics such as the magnitude of magnetization, labelling efficiency, and relaxation rate will all
influence the sensitivity of tracer detection. The relaxation rate will also, along with the particle core
size, affect the spatial resolution (148). Superparamagnetic Iron has a magnetization 108 times larger
than a proton with a relaxation 104 larger (149). These factors give MPI the potential to have a much
higher sensitivity than standard proton MRI, however, MRI using superparamagnetic contrast agents
continues to outperform MPI in terms of sensitivity due to blooming artifacts. This was described in
the “Iron-Based Cell Tracking with MRI” section. Additionally, as all iron naturally found in the body
is paramagnetic rather than the superparamagnetic iron needed for MPI, tissues will give no signal in
MPI, giving MPI an inherently high CNR (42,133,141-144).
During the early stages of MPI use, researchers relied on SPIO such as Vivotrax (150) or Feridex (151)
which were common MRI contrast agents. While these particles did generate images in MPI, they were
not designed specifically for MPI and thus the sensitivity and resolution suffered. Over the decade and
a half since MPI was first created, companies such as Micromod Partikeltechnologie GMBH
(Synomag-D) have developed MPI tailored nanoparticles (152,153). This was done by altering the
composition, size, and shape of the magnetic core to optimize their detectability with MPI (152).
Synomag-D was used in this thesis and its characteristics for cell tracking are outlined below.
Synomag-D was developed and characterized by researchers at the University of Wuzburg, Germany,
and Micromod Partikeltechnologie GmbH (152). In comparison to Vivotrax, the SNR of Synomag-D
was 4x as high, when normalizing to iron content. Additionally, the full width half max of the
generated point spread function was slightly narrower for Synomag-D than Vivotrax, indicating
superior resolution, although the exact measurements were not given (153). It has been demonstrated
that Synomag-D could be used to efficiently label erythrocytes (154), dendritic cells (155), and cancer
cells (156). When developing nanoparticles for the purposes of cell tracking it is important to
determine biodistribution and clearance of the particle (157). IV injections of Synomag-D and
Vivotrax revealed that both tracers accumulate in the liver and spleen over the first 24 hours of
injection. The blood half-life of 0.62 hours for Synomag-D was slightly longer than the 0.59 hours
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observed for Vivotrax (158) This results in less signal clearance over time. While promising SynomagD has not been fully explored yet for cell tracking.
Incubation of cells with SPIO can result in their uptake by natural processes such as endocytosis, or
uptake can be aided by the use of transfection agents (103). Injection of these cells into animal models
allows for in vivo cell tracking. As the SPIO within cells is detected directly, the number of cells in an
area can be quantified by relating the intensity of the signal to the amount of iron loaded into the cells
(42,133,141-144). This characteristic can only be accurately applied to short-term tracking of dividing
cell populations as the tracer is diluted upon cell division (58-60, 68,69).
MPI has incredible promise for cell tracking due to the unique characteristics associated with it,
including its high specificity, positive contrast, and ease of quantification. However, relatively low
sensitivity and resolution compared to other more established imaging systems has been a limiting
factor in the application of MPI for in vivo applications. Over the last few years, advancements in MPI
hardware, and tracer technology have greatly improved both sensitivity and resolution of this modality.
Sensitivity for MPI is defined as the lowest cell number (cellular sensitivity), or volume of iron (tracer
sensitivity), required to produce a detectable signal. Song et al., in 2018 were able to detect as few as
250 cells (7.5 ng of iron; 30 pg iron/cell) in vivo using a custom MPI tailored SPIO (159), while Zheng
et al., estimated that they could detect 200 cells based off the SNR of an image of a 1000 cell (5.36 ng
of iron;26.8 ± 0.3 pg/cell) sample (157).
The highest reported resolution over a three-dimensional area for MPI is around 1mm using a
commercially available SPIO (143,148,153), and 200 μm using MPI optimized nanoparticles (160).
Pushing the limits of MPI even further, the Rinaldi and Conolly groups demonstrated in 2021 the
capabilities of superferromagnetic nanoparticle chains as an MPI tracer. This new development
resulted in sensitivities 40-fold greater than SPIO, with a 10-fold increase in resolution, although exact
resolution and sensitivity limits were not calculated (161). These improved qualities make MPI an
excellent modality for fields such as vascular perfusion (143,162,163), inflammation (164,165), and
most importantly for this thesis cell tracking (133,146)

MPI Cell Tracking
Compared to cell tracking with MRI, MPI cell tracking remains an underdeveloped field.
Limited cell types having been tracked in vivo, and few papers have quantified iron content, or the
corresponding cell numbers (166). Stem cells remain the most widely used cell type for MPI cell
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tracking (132,142,164,167-169), however other cell types including pancreatic islets (170,171), T cells
(172), tumor-associated macrophages (173), neural progenitor cells (157), dendritic cells (155), patient
derived xenografts (174) and breast cancer cells (42,175,176) have been tracked in vivo.
Human embryonic stem cells (hESC) provided a relatively simple model for the earliest of cell
tracking experiments. Tracking stem cells have high relevance for clinical therapeutics. Additionally,
the relatively low levels of proliferation make tracking with MPI easier. In 2013, Saritas et al., were
the first to demonstrate the ability of MPI to track hESC in a subcutaneous model using the MRI
contrast agent Vivotrax. This paper established that MPI could detect iron oxide loaded cells with high
contrast, no depth attenuation, and no background mouse signal. Additionally, this was the first paper
to show the linearly quantitative nature of MPI. Injection sites containing 2x105 cells, showed double
the amount of signal as injection sites containing 1x105 cells when quantified (141).
While the ability to detect locally administered cells has its uses, such as for stem cell
engraftment, or primary tumor growth, it is important to evaluate MPI’s ability to track cells
systemically. This will provide a useful framework for applications such as cancer metastasis and
therapeutics. A common method for stem cell therapy is the intravenous injection of MSCs, however
an imaging method for this treatment is underdeveloped. Motivated by this, Zheng et al., in 2016
provided the first application for tracking the biodistribution, engraftment, and clearance of
systemically administered cells with MPI. MSC were labelled in vivo and injected intravenously into
healthy rats. Cells were immediately observed in the lungs, supporting earlier findings that
systemically administered MSC could become trapped in the lungs of patients. Within 24 hours, cells
the majority of signal shifted to the liver and spleen indicating clearance. Clearance continued over the
12 days post injection, with a blood half-life of 4.6 days. Ex vivo histology and plasma spectrometry
confirmed the anatomical localization of the SPIO tracer. This was the first experiment to show the
clearance pattern of SPIO labelled cells. This is important when considering background signal in an
image and whether it is a result of clearance (167). Zheng et al., also demonstrated in a 2015 paper that
Vivotrax labelled neural progenitor cells could be implanted directly into the brain of mice and imaged
for up to 87 days. This was accompanied by ventricular clearance (157).
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Another example of tracking cells systemically with Vivotrax came from Makela et al., in 2020. This
group successfully labelled tumour associated macrophages via intravenous injection of Vivotrax. MPI
was able to detect signal in the lungs of mice, a feat not accomplished by MRI (173). This could only
be done ex vivo, however, due to gastrointestinal signal.
The majority of early MPI papers have used Vivotrax as their tracer, however, later studies have shown
significant limitations in using these repurposed nanoparticles. Vivotrax has a bimodal distribution of
iron cores. Only 30% of the core particles are the right size for MPI (24 nm), with the remaining 70%
being only 5 nm. This means that only a small fraction of the iron within Vivotrax contributes to the
MPI signal (177). Bulte et al., in 2015 were the first group to use MPI tailored nanoparticles for stem
cell tracking. This research was motivated by the loss of availability of two commonly used SPIO in
Vivotrax and Feridex, which spurned the development and characterization of new nanoparticles. An
MPI tailored nanoparticle, denoted “UW”, was compared against both Vivotrax and Feridex for
tracking of stem cells labelled in vivo. The new particle, specifically designed with MPI in mind, had a
monomodal distribution of cores (19 nm), compared to the bimodal distribution of Vivotrax. This
allowed for a larger fraction of the iron to contribute to the MPI signal. However, Ferguson et al., have
shown that MPI signal will increase with magnetic core size from 14 to 27 nm for monodispersed iron
particles, meaning this particle could be optimized further. Nonetheless, the UW had a slightly higher
MPI signal per unit of iron than Vivotrax, allowing for detection of 5x104 cells. Bulte et al., also
showed that there was a strong relationship between the MRI and MPI signal locations. This helped
cement the idea that MPI could be used to accurately track cells in vivo (132).
Since 2015, several new nanoparticles have been developed with MPI in mind. These include LS-008
from Lodespin Labs LLC , Janus nanoparticles from the Rao lab at Stanford, and Synomag-D from
Micromod. As mentioned before, Vivotrax has a bimodal distribution of core sizes, with only a small
fraction being of an optimal size for MPI. In contrast, these MPI tailored nanoparticles have cores of
uniform size, all of which are in the optimal size range for MPI. This results in superior signal output
per iron and sensitivity compared to Vivotrax. Yu et al., intravenously administered LS-008 where it
was taken up by subcutaneously implanted breast cancer cells in situ, in part due to the EPR effect.
This was the first paper to image cancer cells with MPI using systemically administered nanoparticles.
(42).
The Rao Lab at Stanford., were another earlier group to utilize MPI for cancer cell tracking using MPI
tailored nanoparticles. HeLa cells were labelled with Janus SPIO developed in house and imaged on
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MPI, MRI, and fluorescence imaging. They found that MPI could detect as few as 250 cells, with
superior SNR to that of MRI and fluorescent imaging (32). Additionally, this group was able to detect
cancer cells 20 days post injection, with only a 20% reduction in signal. This indicates the potential for
long term tracking of some cancer cells (32).
Additionally, Makela et al., demonstrated that cancer cells could be tracked with MPI following
labelling with micron sized paramagnetic iron oxide particles (MPIO) (Bang’s Beads) (176). While not
specifically tailored for MPI, MPIO do offer some unique advantages over standard MRI contrast
agents. MPIO are far larger than nanoparticles which means that cells labelled with these particles
typically contain around 3-fold more iron than those labelled with SPIO, increasing the signal output
and sensitivity (178) The use of MPIO MPI offered high specificity and quantification in cancer cell
imaging which was combined with BLI and CT to longitudinally monitor cancer cell implantation,
tumor growth, and metastasis (176). The multimodal approach to this research will be expanded upon
in section 2.3.
A focus in our lab over the last few years has been the tracking of various cell types in vivo using MPI.
Sehl et al., were the first group to combine MPI with 1H MRI and 19F MRI for cell tracking. Feraheme
(Feramoxytol) labelled MSC implanted into the hindlimb of mice were tracked with MPI and 1H MRI
while Macrophages labelled intravenously with perfluorocarbon were tracked with 19F MRI. This
unique multimodal approach allowed for quantitative monitoring two distinct cell populations. MSC
delivery, and number over time was tracked with MPI, while inflammation could be quantified with
19

F MRI. This highlights one benefit of multimodal imaging with MPI. A reoccurring limitation of

MPI was brought up in this paper, however. An undesired gut signal was observed in all mice imaged
caused by iron in the mouse feed. This can cause problems when trying to image signal close to the gut
region (Sehl et al., 2019). In a follow up paper by Sehl and Foster, the in vitro sensitivity for MPI and
19

F MRI were compared for both MSC populations They found that MPI had the potential to be more

sensitive than 19F MRI for cell detection. MPI was able to detect 4000 Vivotrax labeled MSC cells (76
ng iron) compared to the 256000-cell limit (9.01 x 1016 19F atoms) found for 19F MRI. The
implementation of longer scan times allowed for detection limits of 2000 MSC (38 ng of iron), and
4000 4T1 breast cancer cells (37 ng of iron) in vitro (175).
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In 2020, Parkins et al., demonstrated for the first time the ability to track systemically administered
circulating tumor cells (labelled with the MPIO Bang’s Flash Red) homing to mammary fat pad
tumors. Iron content in the primary tumor (0.789 ± 0.184μg), and contralateral mammary fat pad
(0.318 ± 0.044μg) could be quantified with MPI; an important step in developing this clinically
relevant model for cancer therapeutics (179). Later in 2020, Melo et al., tracked, and quantified
metastatic cancer cells with MPI. This research successfully detected as few as 5 x 104 MPIO labelled
breast cancer cells in the brain of mice. The linear relationship of MPI signal to iron content in MPI
allowed for quantification which was not possible with MRI (180). In 2021 Gevaert et al., for the first
time tracked Synomag-D labelled dendritic cells implanted in the footpad of mice with a sensitivity of
approximately 4000 cells. It is estimated that only a small fraction of dendritic cells (10%) reaches
their desired destination, prompting the need for a sensitive and quantitative imaging modality. MPI
was used in this study as it overcomes the sensitivity issue of 19F MRI, and the quantification
difficulties of 1H MRI. Additionally, this paper demonstrated a technique for minimizing gut signal
which was modified for this thesis. Mice were fasted for 12 hours prior to imaging and given laxatives.
Bedding was replaced with a corn based alternative. This successfully reduced gastrointestinal signal
to a point where it was not visible in the dynamic range of tumor signal (155). Knier et al., were the
first group to successfully label patient derived metastatic breast cancer cells with Synomag-D and
detect them in the brains of mice in vivo (174). This paper will be expanded upon in section 2.3.
While MPI is an exciting new modality for cell tracking, it is not without its flaws, however. Firstly, as
mentioned before, researchers have observed a characteristic background gut signal as a result of the
clearance pathway, and contaminations in food and bedding. Secondly, no anatomical information is
given for MPI, requiring the co-registration of CT or a bright field (BF) photograph. Additionally,
spatial resolution is currently low for MPI, making it difficult to differentiate between closely situated
regions. Finally, MPI signal will decrease over time due to cell proliferation, cell dispersion, and
clearance preventing the indefinite tracking of dividing cell populations, as outlined in section 2.1.1.
To minimize the impact these limitations, have for cell tracking, as well as to add new unique
advantages, our lab has turned towards combing MPI with optical imaging modalities such as BLI.

1.2.2 Reporter Gene Imaging (Indirect Labelling)
The second category of cell labelling is reporter gene imaging, what has also been called indirect
labelling (52,181,182). This is a more complicated technique as it involves genetic modification of a
cell’s genome. This method takes advantage of the host cell machinery to produce a reporter protein,
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such as a luciferase or fluorescence protein (52,181,182). As the label is genetically encoded, each
daughter cell will receive their own copy of the reporter gene upon cell division. This allows for long
term tracking of proliferation and cell migration. Additionally, most protein reporters are quickly
denatured upon cell death, allowing for tracking viability as no exogenous signal is produced
(52,181,182). Due to these reasons, reporter gene imaging can be used to track cells indefinitely.
Due to the required genetic modification, researchers using indirect labelling run the risk of altering
cell phenotype and causing unforeseen genetic effects (183-185). Expression of transduced proteins
may be regulated, and silencing may halt expression (183-185). For these reasons, it is harder to
translate indirect labelling to a clinical setting compared to direct labeling, but recent successes of
reporter gene imaging in patients have paved the path to using this technique in more studies interested
in tracking cell-based therapies and other applications (186-189).

Bioluminescence Imaging (BLI)
Bioluminescence imaging (BLI) is an optical imaging modality that takes advantage of the natural
process of bioluminescence to locate cells in preclinical models (190-193). If you have ever seen a
firefly light up the sky, or pictures of angler fish luring in prey, you are familiar with bioluminescence.
This is a natural phenomenon exhibited by roughly 75% of marine animals (194,195) as well as many
terrestrial insects (196) as a method to attract mates, mark territory, communicate, or lure prey (196199). Different animals produce light at different wavelengths, resulting in a full spectrum of colours
(200).
Fascinated by this process, scientists have isolated many of the genes responsible for bioluminescence
and transduced them as reporter genes for imaging. Over time, modifications have been made to
existing bioluminescence reporter genes or their substrates to increase signal intensity or change the
resulting wavelength of the emitted light (201-203). Luciferases are a generic term for an enzyme
capable of catalyzing the oxidation of luciferin protein to an oxyluciferin. This is often done in the
presence of ATP and oxygen; however, this is not required for all luciferases. This reaction, known as
the bioluminescence reaction, produces light as a by-product. The produced light is what gives signal
in BLI. BLI is based on the transduction of a luciferase reporter gene into your cells of interest. After
this, cells can transcribe and translate the luciferase gene into protein using their own host machinery.
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The produced light is detected by a cooled charged-coupled detector (CCD) camera that is in attached
to a light-tight box that the animal is placed in. CCD cameras are devices capable of converting light
into electrical potential. This produces the spatially localized signal and the resultant images in BLI
(190-193).
The first, and by far most common luciferase used for BLI is firefly luciferase (Fluc) and its substrate
D-Luciferin (D-luc). First cloned in 1985 (204) from the North American Firefly (Photinus pyralis)
and used as a reporter for assays three years later (205). Since then, a variety of luciferases have
become commercially available including those from sea pansy (Renilla;Rluc) (206-208) , click beetle
(Pyrophorus plagiophthalamus) (209-211), jellyfish (Aequuorea; Aequorin) (212-214), and several
bacterial species (Vibrio fischeri, Vibrio harveyi) (213-217). Each luciferase/luciferin pair offers
unique characteristics, including the colour produced, the cofactors required, and the sensitivity of
imaging (190,200)
Unlike with fluorescence imaging, there is little endogenous BLI signal in mice and thus BLI offers
high specificity for visualization of cells models (190-193). Due to this, BLI has seen heavy use for
tracking stem cell (218,219) and immune cell therapies (220,221) in vivo. Tracking stem cells is an
important step in determining the efficacy of stem cell therapy for conditions such as cardiac (222,223)
and brain injuries (224,225). BLI allows for visualization of stem cell migration, proliferation, and
implantation (218,219,223). BLI makes it easier to determine that systematically injected stem cells are
localizing to the area of interest and proliferating to fill their need (218,219). Additionally, BLI has
been used to track various immune cells including T cells (227,228), Natural Killer cells (229-31), and
dendritic cells (232,233). Immune cell development, migration to infection sites, and interactions with
other immune cells can all effectively be studied with BLI (220,221). Tracking immune cells can go a
long way in helping understand disease states, developing and optimizing therapeutics, and guiding
cancer immunotherapy.
In addition to tracking stem cells and immune cells, BLI excels at tracking cancer cells, due to its
unique ability to track cancer proliferation sensitively and specifically over long durations; a hallmark
of cancer (234-236). BLI has been used extensively in literature to track cancer progression, examining
cancer metabolism (237-242), apoptosis (243-245), tumor hypoxia (246-248), angiogenesis (249,250),
and most importantly for the purposes of this thesis, tumorigenesis, and metastasis (251-255).
The growth and proliferation of cancer cells is something often studied using BLI in preference over
other imaging modalities, where cells can be detected in as little as a few minutes post injection and
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will show a logarithmic increase over the lifetime of the cell line (190,251). BLI has characteristically
high sensitivity, especially for superficial regions. Sensitivity in BLI is the minimum number of cells
required to produce a detectable number of photons at a specific depth. BLI allows for single cell
detection (256), although the sensitivity of standard BLI drops drastically with depth (190-193). The
high sensitivity of BLI for superficial regions has been used for detecting small tumor lesions and the
early stages of cancer metastasis (257-259). This quality was expanded upon by Momcilovic and
Shackelford in 2018, who showed that BLI could detect superficial tumours at earlier stages than MRI,
CT, and PET, due to the ability to detect fewer cell numbers (242). Although in a different study
conducted by Puaux et al., in 2011 showed PET had a 22% higher sensitivity than BLI when detecting
deeper gastric cancer cell lesions. This was explained by the light attenuation and scattering observed
at depth in BLI. Puaux et al., found that BLI was best for detecting well defined superficial tumors.
BLI as with FLI proved to be the two most practical techniques for measuring tumor burden. Both BLI
and FDG-PET could identify nonpalatable tumors in mice, a feat not accomplished by MRI or FLI
(260).

Akaluc and Akalumine
A significant limitation of BLI is that light is attenuated by biological tissue. As light travels through
an animal, a significant portion of the energy is absorbed or scattered by the surrounding tissue. This
greatly reduces the possible signal as well as introduces depth effects (190-193,234). Signal generated
from deeply situated tissues such as the brain will show a lower signal compared to superficial signal
due to the increased attenuation, resulting in low three-dimensional resolution. The sensitivity of BLI
is greatly dependent on the depth of imaging (190-193, 234). 3D BLI exists to counteract some of
these depth issues, but its use is not that widespread right now as it takes more time to image one
mouse and thus is not as high throughput as 2D BLI (261).
The improvement of matched BLI reporters and their substrates is the focus of many academic and
industrial scientists. Numerous Luciferin, and Luciferase analogues have been developed in recent
years to improve one or more aspects of BLI. To combat the depth effects prevalent in BLI,
researchers have turned towards luciferin analogues which produce light in the far red, or near infrared
range (λmax of 650-900nm) (262). Red shifted light, especially light with wavelengths in the near
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infrared range, have lower attenuation in biological tissue. Hemoglobin, myoglobin, and melanin all
have a lower excitation coefficient (absorption coefficient) for light in the near infrared range (263).
This can be visualized in Figure 1.5, using Akalumine-HCl as an example (264).
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Figure 1.5:

562 nm

677 nm

Figure 1.5. Schematic of haemoglobin light absorbance in relation to the emission spectra of BLI
reporters. The extinction coefficient of oxygenated haemoglobin (black dashed line) is dependent on
the wavelength of light. Based on this coefficient, blue light is more readily absorbed than red light. Dluciferin oxidized by Fluc (blue line) has a peak emission wavelength of 562 nm, corresponding to green
light. This restricts Fluc to imaging superficial tissue as it is readily absorbed by haemoglobin.
Akalumine-HCl oxidized by Akaluc has a peak wavelength of 677 nm, falling in the red-light range.
Haemoglobin has a lower extinction coefficient at this range allowing for deep tissue imaging.
Haemoglobin extinction data taken from the American Chemical Society, 2010 (263). D-Luciferin and
Akalumine-HCl emission spectra data taken from Kuchimaru et al., 2016 (264).
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Having a lower absorption coefficient means less light is absorbed or scattered by the biological tissue
(265,266). This results in a few key advantages when looking at BLI signal. Firstly, signal produced in
deeply situated tissues can now be detected by the CCD camera. This is especially important when
studying tumours or metastases located in deeper tissues such as bone marrow, and the brain; two of
the more difficult organs to image with BLI. Being able to generate signal from these locations leads to
a more complete picture of where metastases are located, and how they are progressing Additionally,
as less signal is attenuated, BLI reporters that utilize near infrared wavelengths will have a higher
sensitivity to lower cell numbers than those with shorter wavelengths. Fewer cell numbers can be
accurately detected, which can be beneficial when looking at the early stages of tumor formation (262).
Several luciferin analogues that produce red shifted light have been developed, including the naphthylluciferin NH2-NpLH2 (201,267), seMpai (268,269), Furizamine (Nanoluc & Antares substrate) (270272), and Akalumine (273,274) among others. Akalumine in particular has shown single cell
sensitivity at depth in vivo, making it a promising option for cell tracking. In 2016, Japanese
researchers led by Takahiro Kuchimaru and Satoshi Iwano synthesized the NIR luciferin AkalumineHCl from the common D-luciferin substrate. D-luciferin was converted into Akalumine by replacing
the aromatic structure to that of a benzothiazole moiety. This change resulted in a maximum emission
wavelength of 675nm, which is red-shifted from the maximum emission wavelength of 562nm
observed in D-Luciferin (264,273). While this new product showed a markable improvement from DLuciferin, Akalumine showed poor water solubility due to the hydrophobicity. This results in poor in
vivo application. To address this concern, Kuchimaru et al., made the water soluble derivative
Akalumine-HCl which emitted light at 677 nm (274).
Kuchimaru and Iwano went on to test their new BLI reporter system against the standard pair of DLuciferin and FLuc (FLuc BLI). In a tissue phantom, Akalumine-HCl had 8.3 times higher depth
penetration than D-Luciferin at a depth of 8mm, indicating the potential for imaging deeply situated
tissues. The in vivo BLI performance was tested using two deep tissue in vivo models: lung cancer and
brain striatum of mice. Akaluc BLI produced signal 52 times greater than FLuc BLI when detecting
small metastases in the lungs of mice. This is significant as lungs are one of the most common sites of
metastases, and the early detection of these could greatly improve therapeutics. Further, cells injected
into the striatum of living mice produced signal an incredible 1408-fold greater for Akaluc BLI than
FLuc BLI (274). This can be attributed to (i) D-Luciferin does not readily cross the blood brain barrier
as described by Mofford & Miller (275) while Akalumine-HCl crosses in much higher concentrations
(274) (ii) Akaluc has a catalytic activity 7-13 times that of Fluc. (iii) The brain is one of the deepest
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situated organs, resulting in more attenuation for Fluc BLI compared to Akaluc BLI. To further
demonstrate the incredible sensitivity Akaluc BLI offered, Kuchimaru and Iwano went on to detect
single cells implanted 4.8mm deep in the brains of marmosets (274). Until this point, BLI was limited
to small animal imaging.
Since the development of Akaluc BLI by Kuchimaru and Iwano, several groups have utilized this
system to track various cell types in vivo. In a 2020 paper, Su et al., tracked the migration of CAR-T
cells for osteosarcoma treatment (276). As reported by Iwano et al, Akaluc BLI offers 13-fold greater
signal output per reporter molecule for intrapulmonary locations (274). This increased signal allowed
Su et al., to detect cells in the deeply situated lung tissues (276). Liu et al. used this system to track
metastasizing breast cancer cells in a novel model of synchronous bilateral breast cancer (277). The
sensitivity of Akaluc allowed for visualization of metastases in the lungs of mice 13 days sooner than
when using a different high sensitivity BLI reporter Antares2. Researchers from the University of
Tokyo tracked the engraftment of MDS-L cells (for the hematological malignancy Myelodysplastic
syndrome) in the brain of mice using a xenograft model. The brain is historically a very difficult region
to image with BLI due to its depth, shielding by the skull, and the inability for substrates to cross the
blood brain barrier (BBB), however the high sensitivity of Aklauc BLI and the increased tissue
permanence of Akalumine-Hcl compared to D-luciferin (264) allows for visualization of brain cells.
(278). Bozec et al., successfully tracked patient derived glioma stem cells transplanted intracranially
in mice. In a comparison to Fluc BLI, Akaluc BLI produced a 100-fold greater signal in vivo allowing
for detection of as few as 5000 deeply situated brain glioma cells (279).
While the literature regarding Akaluc BLI’s use in tracking cancer cells over long durations is sparse,
the papers presented by Iwano et al., Kuchimaru et al., Su et al., Liu et al., Zhong et al., and Bozec et
al., highlight the potential for BLI with the Akaluc and Akalumine. Akaluc BLI promises higher
sensitivity tracking of cancer cells due to the increased production of light using Akalumine-HCL, as
well as the decreased light attenuation. Akaluc BLI allows for tracking early stages of metastases in
previously inaccessible organs such as the lungs and brain, giving a more complete picture of
metastasis, as well as treatment outcomes (264,274,276-279).
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Although the implementation of NIR, Akaluc BLI overcomes many of the limitations prevalent in
standard FLuc BLI, it is still not a perfect system. Francesco Amadeo et al., noted that Akalumine-HCl
saturates Akaluc at a far lower concentration than observed in FLuc BLI. For substrate concentrations
far exceeding the standard dose, this may result in FLuc BLI actually having a higher sensitivity than
Akaluc BLI when substrates are administered subcutaneously (280). Additionally, a background liver
signal has been reported by multiple groups after intraperitoneal of Akalumine-HCL, without the
presence of Akaluc (268,276,280). Multiple papers have also noted that in comparison to other BLI
reporters, Akalumine-HCl was more acidic, resulting in increased cytotoxicity (268,281). Lesions may
also form surrounding the injection site (280). Further, the stronger signal produced by Akaluc BLI
may actually hinder the examination of secondary signal locations. If the signal originating from the
primary tumor is too large, it will saturate the CCD camera, preventing visualization of regions with
low cell numbers such as metastases. A common practice to minimize camera saturation in BLI is to
cover the primary signal location with a dark opaque shield. While useful, this technique may also
block secondary regions close to the primary tumor. Lastly, BLI is still limited by substrate
availability and genetic modification, reducing its potential for clinical translation. To date, Akaluc
BLI has not been combined with a medical imaging system for multimodal cell tracking, the
application of which should minimize the limitations of this modality.

1.2.3 Multimodal Optical and MPI Studies
No imaging modality is perfect and is associated with its own limitations. For the best results when
tracking any cell type, it may be beneficial to combine multiple modalities together, combining the
strengths of each modality while minimizing their unwanted limitations. MPI relies on directly loading
cells with a SPIO and can provide excellent cell detectability but can be limited to short-term tracking
of highly proliferative cancer cells due to dilution of label over time. Combining MPI with an optical
imaging modality such as BLI can allow for highly sensitive short-term tracking with MPI and longerterm tracking of viable cancer cells with BLI.
Several groups have combined MPI and optical imaging together. In 2017, Yu et al., became the first
group to image tumors with MPI after systemic injection of nanoparticles. BLI was used on day 1 of
this proof-of-concept study to confirm the MPI findings. High concordance was found between MPI
and BLI signals at this early time-point (42). Using optical imaging as a positive control for signal
location is a common practice for MRI. Another application for multimodal imaging is the industrial
development of functionalized tracers. In 2015, Arami et al., systemically administered MPI tailored

27
nanoparticles with fluorescent moieties, and tracked their biodistribution and clearance with MPI and
fluorescent imaging (282). This was followed by their 2017 paper which detected brain cancer cells
labelled with PET and FLI functionalized MPI nanoparticles in both xenograft and murine models
(283). In 2019, Song et al., developed their own multimodal nanoparticles capable of producing
contrast in MPI, MRI, photoacoustic imaging, and fluorescent imaging. This nanoparticle was used to
track brain and breast xenografts in both subcutaneous and orthotopic models with both optical and
medical imaging systems. Additionally, the biodistribution and clearance was assessed with MPI over
an 85-day period, marking one of the longest MPI experiments to date (284).
Jung et al., in 2018, developed a novel theragnostic technique for treating and imaging the hypoxic
region of tumors. Exosomes, isolated from human MDA-MB-231 breast cancer cells were modified to
carry the therapeutic Olaparib, along with Vivotrax, and a probe based fluorescent agent in DiO. The
uptake of these exosomes by tumors, and the simultaneous treatment, was imaged using MPI and
fluorescence microscopy, marking the first time MPI has been used to track exosome biodistribution.
The use of fluorescence probe allowed for visualization and quantification using fluorescence
microscopy, and a measure of exosome uptake, and apoptosis using flow cytometry (285).
The papers highlighted so far have either used functionalized nanoparticles (42,282-284), or
fluorescent probes (285). While these methods have their advantages, such as the ability to add
targeting moieties, and ensuring that MPI and optical imaging signals are originating from the exact
same location, they are also inherently limited in their application. By utilizing fluorescent moieties or
probes rather than transduced reporter gene constructs, optical imaging is subject to the same
limitations of probe-based imaging described in section 1.2.1. and cannot be used to track viability and
proliferation in dividing populations indefinitely.
Few researchers have combined MPI with reporter gene-based optical imaging for long term tracking
of cells. The use of reporter genes rather than fluorescent moieties provides a measure of long-term
visualization of viability and proliferation. Early in 2021, Knier et al., from the Foster lab, tracked
patient derived xenograft (PDX) cells using MPI and Fluc BLI. Human breast cancer cells, derived
from patient brain metastases were engineered to express firefly luciferase, and labelled with SPIO and
injected into the fourth mammary fat pad of 5 mice. 2 mice were imaged on BLI for up to 49 days,
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while the other 3 mice were imaged on MPI until day 28. It was found that MPI signal decreased over
time, while BLI signal increased. While promising, this paper was not a direct comparison between the
two modalities. Separate mice were imaged on BLI and MPI. Secondly this paper used Fluc as its BLI
reporter rather than the more sensitive Akaluc (174).
Additionally, Makela et al., tracked the fate of breast cancer cells with MPI, BLI and CT in vivo. 4T1
cells transduced to express Luciola Italica luciferase (Red-FLuc), and labelled with Bang’s Beads
(MPIO), were injected into the mammary fat pad of mice. This paper successfully demonstrated the
ability to track cancer progression and potential metastasis with BLI and MPI, however BLI signal was
not quantified, and therefore could not give a complete picture of cell numbers over time (176). The
BLI reporter Red-FLuc has a red-shifted emission spectra (peak wavelength = 617 nm) compared to
standard Fluc BLI. Although no direct comparison of Red-FLuc and Akaluc BLI has been done, based
on the absorption spectra of biological tissues (265,266), Akaluc BLI (peak wavelength = 677 nm)
should have far superior depth penetration and therefore sensitivity. No one has yet combined MPI
with Akaluc BLI for tracking of any cell type in vivo. This work explores the combined modality
strategy to image spontaneous metastasizing cancer cells in a preclinical mouse model.
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Chapter 2
This chapter will highlight all experiments conducted for this thesis. The data presented is in the form
of an integrated paper.

Abstract
Magnetic particle imaging (MPI) is an emerging technology used to directly visualize and quantify
superparamagnetic iron oxide (SPIO) nanoparticles in vivo. Compared to the more conventional ironbased cellular MRI method, MPI provides positive contrast and quantification of cell number at initial
implantation. Bioluminescence imaging (BLI) with the highly sensitive reporter gene Akaluc can
provide complementary information on cell viability and thus, we explored combining these
technologies to provide a more holistic view of cancer cell fate in mice. Murine breast cancer cells
stably expressing Akaluc and TdTomato were labeled with an MPI tailored nanoparticle, Synomag-D,
and injected into the mammary fat pad (MFP) of nude mice. BLI was performed on days 0, 6 and 13
and MPI was performed on days 1, 8 and 14. BLI signal in the MFP increased significantly from day 0
to day 13 as a result of tumour growth. MPI signal significantly decreased from day 1 to day 14 as a
result of probe dilution in proliferating cancer cells. BLI signal significantly increased from day 0 to
13. Secondary metastases were detected with both modalities, although they were visualized in
different locations throughout the body. Overall, Akaluc BLI complemented our MPI cell tracking
technique, allowing for longitudinal measures of cell viability and highly sensitive detection of distant
metastases. We predict this multimodal imaging approach will be useful in evaluating novel
therapeutics and gaining a better understanding of the mechanisms contributing to metastasis.
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2.1 Introduction
At least two thirds of cancer deaths can be attributed to metastasis in vital organs such as the brain,
lungs or liver (1,2). Despite these staggering numbers and the significant amount of research devoted
to this field, many of the biological mechanisms responsible for cancer metastasis remain unclear. As a
result, the development of effective treatments is difficult and patient outcomes are variable (3).
Preclinical animal models are valuable in optimizing and evaluating novel treatment strategies in vivo.
They allow for longitudinal and dynamic studies to be carried out within an intact, living subject rather
than at the cell or organ level. To enable monitoring cancer cells over time, imaging technologies have
been used extensively in preclinical models to noninvasively visualize and quantify cell proliferation,
migration and viability (4).
Cellular MRI is one of the most common techniques for in vivo cell tracking due to unrivaled soft
tissue contrast and high spatial resolution. MRI cell tracking is typically done by labeling cells with
superparamagnetic iron oxide particles (SPIOs) which cause a distortion in the magnetic field,
resulting in a loss of signal or signal void (5-9) This signal void appears as a dark region within the
image. By employing this technology, our group and others have previously demonstrated the ability to
detect down to a single cell or particle in a variety of preclinical animal models (10-15). However, the
dark signal voids generated by SPIOs, makes it difficult to discern cells from other naturally dark
regions throughout the body such as blood or air. Within the magnetic field, the iron also causes a
blooming effect such that the area of signal loss in the image appears larger than the cell itself (16,17).
Importantly, this makes the quantification of iron-labeled cells difficult since the relationship between
the signal detected in vivo and the number of SPIO-labeled cells injected is not linear (18-21).
Therefore, an alternative imaging modality that provides positive contrast and can more readily
quantify the number of SPIO particles and/or SPIO labeled cells would be highly valuable to the cell
tracking field.
Magnetic particle imaging (MPI) is an emerging imaging technology that works by directly detecting
iron nanoparticles and thus, may be a valuable tool for in vivo tracking and quantifying SPIO-labeled
cells (22,23). In MPI, two electromagnets are positioned opposite each other, producing opposing
magnetic fields. In the centre of the two magnets is a “field free region” (FFR) where there is a zero-
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net magnetization. When this FFR passes over free or loaded SPIO, the magnetization of the particle
flips, resulting in a positive signal. Since only SPIO can be detected with MPI and there is no
endogenous SPIO in biological tissues, there is no background signal associated with MPI. This results
in MPI having a relatively high specificity but reduced cellular resolution when compared to MRI.
Furthermore, in MPI, the amount of SPIO present is linearly proportional to the amount of signal
detected and allows for calculation of cell number if the concentration of SPIO per cell is known
(21,24-28). Recent advancements in tracer development have quickly led to improved in vivo cell
detection limits. Nanoparticles tailored specifically to MPI such as Synomag-D from Micromod
Partikeltechnologie GmbH (29), have shown to have higher sensitivity and resolution than MPI using
non-tailored particles (30). The highest reported sensitivity achieved by MPI to date is 200-250 SPIOloaded cells (31,32). The best resolution reported is 150 μm (33). While MPI overcomes many of the
potential issues associated with cellular MRI, some important limitations still need to be considered.
First, SPIOs can become diluted through cell division, which can result in a loss of signal over time
and difficulties in quantification of cell number, particularly for highly proliferative cells (19) As in
cellular MRI, SPIOs can be expelled from dead cells and taken up by non-transplanted cells such as
macrophages, leading to false-positives in MPI (34). Finally, MPI will produce the same signal
regardless of whether the SPIO-labeled cell is dead or alive, and thus, MPI and MRI are not feasible
modalities to assess and visualize cell viability. (34).
Bioluminescence imaging (BLI) has been widely used for preclinical cancer studies, offering a
relatively inexpensive tool to evaluate cell migration, proliferation, and viability (35-42). For BLI, a
luciferase reporter gene is introduced into the host cell genome through viral or non-viral methods. The
luciferase will react with an administered substrate and produce light as a product of oxidation, which
gets collected by a cooled CCD camera. Compared to MPI, BLI requires stable reporter gene
expression with each daughter cell receiving a copy or copies of the luciferase reporter gene upon
division, and thus BLI does not suffer from label dilution over time (43-45). This makes BLI an
advantageous imaging tool for longitudinal cancer studies since highly proliferative cells can be
monitored over time. Importantly, the majority of luciferases require ATP and oxygen as cofactors in
the enzymatic reaction, resulting in signal that is representative of live cells only. Unlike the
autofluorescence that is commonly observed in fluorescence imaging, there is little endogenous
bioluminescence in the body, giving BLI relatively high CNR (46). However, optical imaging is
limited by depth of penetration since light is attenuated by biological tissue resulting in decreased
signal at greater depths. As a result, BLI is primarily restricted to small animal imaging (35,47-50).
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In recent years, developments in reporter gene systems have addressed some of the limitations of
conventional BLI. Akalumine, a new substrate derived from D-Luciferin by replacing the aromatic
structure with a benzothiazole moiety, has greatly minimized the depth effects typically associated
with tissue attenuation observed in BLI. Akalumine is a BLI substrate that releases light in the Near
Infrared Range (NIR) when catalyzed by Akaluc, which is less attenuated by biological tissues (51-53).
Utilizing this system, researchers have demonstrated the ability to detect single Akaluc expressing
HeLa cells trapped in the lungs of mice (53). Further, through the use of Akaluc BLI, Iwano et al.,
were even capable of detecting BLI signal in the brains of marmosets, providing evidence of greatly
improved sensitivity (52). Even with these advancements however, BLI remains a pre-clinical imaging
modality due to the high concentrations of substrate which would need to be administered in patients.
The combination of using two or more imaging systems, commonly referred to as multimodal imaging,
provides a more complete picture of cancer cell fate in vivo. Multiple modalities can provide
complementary information on a given disease state while overcoming some of the existing limitations
of using a single imaging modality. The purpose of this study was to combine MPI and Akaluc BLI
for high sensitivity cancer cell tracking in a murine model of triple negative breast cancer.

2.2 Materials and Methods
2.2.1 Cell Line Origins and Culture
4T1Br5 cells were generously provided by Dr. Patricia Steeg’s lab. Cells are a derivative of 4T1
murine breast cancer cells, with preferential metastasis to the brain. The 4T1Br5 cells were maintained
in T75cm2 flasks with 10mL of Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal
bovine serum (FBS) and 1% antibiotics. Cells were grown under 37 37°C and 5% CO2. Passaging was
conducted every 4 days, using 0.25% Trypsin-EDTA to unadhered cells from the flask.

2.2.2 Transduction of 4T1Br5 cells with TdTomato-Akaluc
4T1Br5 cells were transduced with lentivirus to express a construct consisting of a pEF1 α constitutive
promoter driving both TdTomato and Akaluc. To evaluate whether the construct was successfully
introduced into the 4T1Br5 cell line, the expression of tdTomato was measured through flow
cytometry using a FACS Canto Cytometer. The expression of TdT was assessed at passage 3, 4, and 10
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to evaluate construct stability. Reporter gene expression was further visualized using an
epifluorescence microscope using an EVOS FL Auto Imaging System (Thermo Fisher Scientific).

2.2.3 Cell Characterization
The relationship between cell number and BLI signal for transduced cells was evaluated by seeding
cells on a 24 well plate in 500uL at the following cell counts: 1x106, 5x105, 2.5x105,1.25x105 and
6x104 cells. Prior to imaging, 5 μl of Akalumine-HCl (30 mg/ml; TokeOni) was added directly to each
well. Cells were immediately imaged on an IVIS Lumina XRMS In Vivo Imaging System
(PerkinElmer) until maximum signal flux (Photons/second) was observed. This was done in 3 technical
and biological replicates. Linear regression was used to compare BLI total signal (Photons/Second) vs.
plated cell number.

2.2.4 Cell Labelling
Cell labeling was performed with the SPIO, Synomag-D (Micromod Partikeltechnologie, GmbH,
Germany). Synomag-D is a dextran coated MPI tailored nanoparticle that has a 30 nm nanoflower core
and a 50 nm hydrodynamic diameter (10 mg/ml iron content). No surface functionalities were added.
4T1Br5 cells (105) were seeded in a T75 flask and grown until 80% confluency was reached. Cells
were washed with PBS and then added to a new T75 flask containing 5 mL of serum-free DMEM
media (97%), 90 μl Synomag-D (1.7%) (Micromod Partikeltechnologie, GmbH, Germany), 60 μl of
Protamine Sulphate (1.2%) (Thermofisher Scientific), and 20 μl of Heparin (0.4%) (Thermofisher
Scientific). After a 4hr incubation period at 37oC and 5% CO2, an additional 5mL of DMEM was
added to the flask. Cells were incubated for a total of 24hrs and then washed with PBS prior to being
used for studies.
To determine whether the cells were efficiently labeled with Synomag-D, a Perl’s Prussian Blue (PPB)
stain for iron was performed. Labeled cells were washed three times with PBS to remove any excess
iron. Iron-labeled cells were imaged at 400X magnification on an EVOS FL Auto Imaging System
(Thermo Fisher Scientific). To calculate labeling efficiency, the number of cells with visible
encapsulated iron particles was divided by the total number of cells in a region. This was sampled at
three fields of view for nine different slides.

2.2.5 Cell Viability
To determine the effect of iron labeling on cell viability, labeled and unlabeled cells were stained with
a 1/100 dilution of Zombie Violet (Fisher Scientific). The working concentration of this dye was

61
determined through titration. Cells were then evaluated using a FACS CANTO Flow Cytometer to
measure fluorescence in the Zombie Violet channel (excitation nm; 450/50 nm bandpass filter). A
“Dead Cell” control, was created via incubation at 56oC for 10 minutes prior to staining, killing
approximately 20% of cells. Additionally, an unstained control was used to set the gating for the
experiment.

2.2.6 In Vitro BLI
To determine the effect of iron labeling on BLI signal, 4x104 labeled and unlabeled cells were added to
a 24 well plate, along with a naïve untransduced, unlabeled population as a negative control. Next, 5 μl
L of Akalumine-HCL (5 mM) was added to each well prior to imaging an IVIS Lumina XRMS In
Vivo Imaging System (PerkinElmer). This was repeated on days 1,3,5 and 7 post iron labeling.

2.2.7 General MPI Scan Setup and Protocol
For in vitro experiments, an empty ELISA well was taped to the bed, in which PCR tubes containing
the experimental samples were placed. For in vivo experiments, mice were placed in the headfirst
prone position within the MPI bed. Legs were extended and taped down to position the primary tumor
within the mammary fat pad away from the body. All scans were conducted under 1-2% isoflurane
administered from a nose cone. A schematic of this setup can be seen in Figure 2.1 below
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Figure 2.1:
A.
A.

B.
B.

C.

Figure 2.1. Schematic of MPI set up. All MPI experiments were conducted on the Momentum Scanner
from Magnetic Insight seen in A. The in vitro set up can be seen in B. SPIO, or cell pellets labelled with
SPIO were loaded into a PCR tube, and placed into an empty ELISA well. This well was taped onto the
bed of the MPI. The in vivo set up can be seen in C. Mice were positioned in the prone position. Hind
legs were extended backwards and taped to the side of the bed. An additional piece of tape was used
around the abdomen to hold the mouse in place. Isoflurane was administered via nose cone by a tube
running beneath the bed.
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2.2.8 Characterization of Synomag-D
The sensitivity and resolution of Synomag-D were characterized using MPI relaxometry, and
compared to the commonly used SPIO, Vivotrax (Magnetic Insight Inc). Three technical replicates of 1
μl of Synomag-D were scanned separately with a full field of view (FOV) (12 cm). This was repeated
for three technical replicates of Vivotrax. The sensitivity of both Synomag-D and Vivotrax was
determined by the amplitude of the point spread function (PSF), while resolution was given by the full
width half maximum (FWHM).
To evaluate the relationship between Synomag-D concentration and MPI signal, dilutions of SynomagD (50 μg/ μl, 25 μg/ μl, 12.5 μg/ μl, 6.25 μg/ μl, 3.16 μg/ μl, 1.56 μg/ μl, 0.78 μg/ μl) were scanned
individually on MPI in triplicates using a full field of view (12 cm). ROIs were drawn based on the
outline described in the “Image Analysis” section. A linear regression was done to correlate iron
concentration to signal. This was conducted using a 3D high sensitivity multichannel isotropic scan (35
projections, 12 cm FOV). The slope of this calibration curve was used to quantify iron content from
MPI images using the formula:
!"#$ &#$'($' (*+) =

.#'/0 12! 34+$/0 (5. 7. )
30#8( #9 &/04:"/'4#$ ;4$(

To determine the smallest mas of iron that can be reliable detected on MP12 Serial dilutions of iron
labelled cells were made with titres of 1.024x106, 5.12x105, 2.56x105, 1.28x105, 6.40x104, 3.20x104,
1.60x104, 8.00x103, 4.00x103, 2.00x103, 1.00x103, 5.00x102 in PCR tubes. Pellets were scanned using
the 2D High sensitivity isotropic mode starting from the highest cell count. The positive signal
detection threshold was set at an SNR of 5 which can be calculated by dividing the mean signal of the
image by the standard deviation of the background signal. This follows the Rose Criterion for visible
signal (54). Cell dilutions having a signal above the threshold (SNR >5), can be reliably detected with
MPI, while cell dilutions below this signal threshold were considered undetectable. The last cell
dilution that exceeded this threshold is said to be the “2D detection limit”. 3D high sensitivity (35
projection) scans were then acquired for dilutions beginning at the 2D detection limit and continuing to
the lowest cell count (8.00x103, 4.00x103, 2.00x103, 1.00x103, 5.00x102). The 3D detection limit was
the last iron dilution which produced a signal greater than the threshold (SNR > 5).

64

2.2.9 In Vivo BLI and MPI
4T1Br5 cells expressing TdTomato and Akaluc were cultured for one week prior to labeling with
Synomag-D. One million cells suspended in 100 ul of PBS were injected into the 4th mammary fat pad
of each mouse (n=4). BLI was performed on days 0, 6 and 13 following injection. Immediately prior to
imaging, an intraperitoneal injection of 100 ul of Akalumine-HCl (5 mM) (Sigma Aldrich) was
administered. Mice were anesthetized using 1-2% isoflurane and positioned supine in an IVIS Lumina
XRMS In Vivo Imaging System (PerkinElmer). Regions of interest were placed over the primary
tumours and images were acquired for up to 30 minutes until peak photon flux (p/s) was reached for
each mouse. Once peak signal was reached, additional images were acquired with the lower half of the
mouse covered with a black cloth to allow for visualization of secondary lesions.
MPI was performed on days 1, 8 and 14 post injection. A schematic for the in vivo experimental
outline can be seen in Figure 2.2. Mice were anesthetized using 1-2% isoflurane and imaged for up to
40 minutes. Mouse food and bedding was removed for 12 hours prior to imaging to minimize any
unwanted signal from the gut which can be caused by iron present in food or bedding. MPI scans were
acquired in 3D mode with 35 projections and a full field of view (12 cm). Mice were placed in the MPI
scanner headfirst in the prone position. Legs were extended and taped to the bed. MPI images were
analyzed in VivoQuant (InVicro). ROI’s were generated automatically for any signal greater than the
set threshold (SNR >5). Quantification was done by comparing the MPI signal to the 3D Calibration
line made earlier. A more in-depth description of the image analysis for both MPI and BLI is outlined
in section 2.2.10.
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Figure 2.2:

BLI
IP injection of 100 ul
5mM Akalumine-HCl
Days: 0, 6, 13
Supine Position

MPI

Days: 1, 8, 14
Prone Position

Mammary fat pad injection of 1 x106
Synomag-D labelled 4T1-Br5-TdTAkaluc cells

Figure 2.2. Schematic of in vivo MPI and BLI experimental outline. Mice were injected with One
million dual labelled 4T1Br5 cells via the 4th mammary fat pad. Mice were imaged on BLI 0-, 6-, and
13-days post cell injection, following the administration of 100 μl of 5mM Akalumine-HCl via
intraperitoneal injection. Scans were done in supine position. MPI scans were conducted 1-, 8-, and 14days post cell injection while mice were in the prone position. All scans done under 1-2% isoflurane
anaesthesia. Figure made in BioRender.
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2.2.10 Image analysis
For MPI, A 3D high sensitivity, isotropic (35 projections) scan was done of an empty bed to determine
background signal. Using the software Vivoquant (Invicro), a region of interest (ROI) was manually
drawn over the entire empty bed. The standard deviation was recorded. Based on the Rose Criterion,
true signal was denoted as anything greater than 5x the standard deviation of the empty bed. ROIs of
samples were drawn by gating for signal higher than the 5x standard deviation. MPI Pictures are taken
in Vivoquant and displaced as a Maximum Projection Images. The total signal present in an MPI scan
can be calculated using the following formula:
.#'/0 12! 34+$/0 = 1(/$ 34+$/0 < =#0>?( (??! )
Iron content present in each lesion was calculated using the formula below:
!"#$ &#$'($' (*+) =
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The mass of iron present in each cell was calculated during the MPI calibrations. The total iron content
determined in a scan was divided by the number of cells imaged. This was repeated for cell numbers of
1.024x106, 5.12x105, 2.56x105, 1.28x105, 6.40x104 and 3.20x104. The calculated values were averaged
to give the rough iron content per cell. Standard deviation is used to show variance.
!"#$ &#$'($' 8(" &(00 (*+) =
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The number of cells in a region can be estimated at early time points by dividing the iron content by
the iron content per cell.
For BLI, regions of interest were drawn around the primary signal as well as any secondary locations
in the body also displaying signal. The ROI was a consistent size between each of the time points. The
average BLI signal in each ROI was recorded.

2.2.11 Statistics
All statistics were conducted using the PRISM 9 software.
Linear regressions were used to plot trends for in vitro BLI signal Photons/s) vs cell number (n=3), the
3D MPI calibration curve, and total in vitro MPI signal vs cell number (n=3). The goodness of fit is
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displayed by r . Significance was determined by P values less than 0.05. Standard Deviation was
calculated for the variance between replicates. All error bars shown represent the standard deviation.
One-Way ANOVAs were used to determine whether different conditions were significantly different.
This was used for both BLI signal and viability for unlabelled vs. iron-labelled cell populations. For
cell detection limit experiments, this was used to compare both the MPI signal (A.U.) and the iron
content (μg) for different numbers of imaged cells. For in vivo experiments, One-Way ANOVAs were
used to compare MPI signals (A.U.) for each day, Iron content for each day, and BLI signal for each
day. Error bars and ± denote standard deviation (n=4). P values are given for each comparison.

2.2.12 Ex Vivo Analysis
Following sacrification with isoflurane, mice were perfused with 4% paraformaldehyde to fix tissues.
The primary tumor and axillary lymph nodes were excised and stored in PBS at 4 °C degrees. A
representative mouse was chosen for ex vivo analysis. Tissues were set on a plastic weighing dish,
which was the placed on the MPI bed. A 2D MPI scan was acquired for each excised tissue sample.
The Primary tumour and lymph nodes were then cut in half for two separate sectioning and staining
procedures. One half of each tissue were embedded in paraffin, sectioned, and stained with Perl’s
Prussian Blue, and Nuclear Fast Red counterstain (Refer to section 2.2.4 for more details on stain).
This was used to determine whether SPIO was present in the tissue sections. Slides were imaged with
brightfield microscopy on a ECHO Resolve microscope at 80 X magnification The other tissue halves
were passed through a sucrose gradient (10%, 20%, 30% sucrose in PBS) and then frozen. Mounting
media containing the fluorescent dye 4’,6’-diamidino-2-phenylindole (DAPI) was applied prior to
imaging frozen sections. DAPI stains the DNA of all cells. Slides were imaged on an ECHO Resolve
microscope with a 670 ms exposure time for fluorescence in the TdT channel, and 35 ms exposure
time for fluorescence in the DAPI channel. Images were taken at 10 and 80 X magnification.
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2.3 Results
2.3.1 Transduction of 4T1Br5 cells with TdTomato-Akaluc
Cells were successfully transduced by the pEF1 α-TdTomato-Akaluc construct and were capable of
producing both the functional TDT and Akaluc proteins, as demonstrated through Flow Cytometry.
Cells successfully transduced with the construct were 77.6% positive for expressing some level of the
TDT fluorophore (Figure 2.3 B). This level of expression remained constant through passages 3, 4, and
10, with fluorescence percentages of 76.9%, 76.3%, and 79.6% respectfully. Fluorescence microscopy
conducted on the same days visually showed similar percentages of cells expressing TdTomato
fluorescence (cells appeared red when expressing TdTomato) (Figure 2.3 C).
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Figure 2.3:
A.
A.

B.

C.

Figure 2.3. Design and validation of Reporter Construct. (A) Vector map consisting of pEF1α promoter,
TdTomato and Akaluc. (B) Flow cytometry of untransduced (blue) and transduced (red) cell populations at
passage 3. Cell Count vs. TdT fluorescence was plotted in a histogram. TdTomato positive cells within gate.
(C) Confocal microscopy further confirms expression of TdT.
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2.3.2 In Vitro BLI
Total photon flux (P/s) measured with BLI was found to be positively and linearly correlated to the
number of cells seeded (p=0.0034, r2=0.9613) (Figure 2.4A, B). There were no significant differences
in BLI signal between any of the replicates. Visually, no discernable differences in BLI signal were
observed over 7 days between labeled and unlabeled cells (Figure 2.4C), and there were no significant
differences between the two cell populations over all time points (Figure 2.4D).
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D.

Figure 2.4. Characterization of Transduced Cells. Total BLI signal versus cell numbers ranging from
6x104- 1x106 cells (A, B). BLI Signal scale shown in Photons per second (P/s). Unlabelled (Black), and
Synomag-D labelled (Red) cells, 1 week post loading (C, D).
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2.3.3 Characterization of Synomag-D
The Relaxometer function on the MomentumTM MPI scanner was used to compare the sensitivity and
resolution of Synomag-D to the more commonly used SPIO, Vivotrax. The sensitivity of Synomag-D
was found to be 141.19 A.U., 3.8 times greater than the 45.10 A.U. measured for Vivotrax (Figure
2.5A), which was significantly different as calculated by an ANOVA (p<0.0001). 2.5B depicts the
resolution for Synomag-D and Vivotrax as calculated by the full width half max (FWHM). For a 6.1
T/m gradient, Synomag-D had a resolution of 2.51 mm, which was 1.35 times greater than the 3.4 mm
resolution calculated for Vivotrax. We found a significant linear relationship between the
concentration of Synomag-D and resulting MPI signal (Figure 2.5C; r2 = 0.9913; p<0.05). Calibration
lines were subsequently used to determine the iron content of unknown samples by dividing the MPI
signal by the slope of the calibration line. The slope was found to be 214.16 (r2 = 0.9913) for the 3D
High Sensitivity Isotropic scan.

2.3.4 Iron Labeling of Cells
A Perl’s Prussian Blue stain confirmed efficient cell labeling (98.9%) where iron appears blue within
the counterstained 4T1Br5 cells (Figure 2.5D). Due to an extensive washing protocol, nearly all iron
appeared to be within the cells, with little extracellular iron observed. Flow cytometry was used to
assess the viability of cells labeled with iron (Figure 2.55E/F). The percentage of cells that were
negative for Zombie Violet (viable cells) remained constant at 85-90% for labeled and unlabeled cells
with no significant differences between the groups detected.

73
Fgg
Figure 2.5:
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Figure 2.5. Characterization of Synomag-D. Relaxometry scans (A, B) were normalized to iron
content for Synomag-D (10 µg/ μl) (red), and Vivotrax (5 µg/ μl) (black). Sensitivity (A), denoted
by amplitude. Resolution (B) shown by FWHM. Synomag-D was 3.8x more sensitive than
Vivotrax per gram of iron. 3D Calibration line (C) was made for a serial dilution of Synomag-D
ranging from 50 µg to 0.7 µg. Calibration line later used to calculate unknown iron content from
known values. Synomag-D loading of 4T1Br5-TdT-Akaluc cells was validated with Perl’s
Prussian stain and Nuclear Fast Red counterstain. Loading efficiency calculated by dividing
number of cells with Synomag-D present by total number of cells (n=9). Viability assay conducted
through Flow Cytometry for unlabelled and Synomag-D labelled cell populations. Viable cells
are negative for Zombie Violet, plotted against Forward Scatter (E, F). Live cells shown in green.
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2.3.5 In Vitro MPI
MPI scans were acquired for 12 different samples ranging from 500 to 1.024 million SynomagD labeled cells (Figure 2.6A). MPI signal could be clearly visualized down to 64 000 cells (0.11 μg of
iron), while background noise became apparent at 16 000 cells (0.02 μg of iron). In Figure 2.6, white
boxes are drawn around “undetectable signal”, which was defined as signal below an SNR of 5 (the
Rose Criterion; Rose, 1984; Bushberg et al., 2002). Cell numbers greater than or equal to 8000 (0.01
μg of iron) were detectable with an SNR of 5 or higher (values above the red dashed line) (Figure
2.6B). Cell numbers greater than or equal to 1000 were detectable with an SNR of 3 or greater (values
above the blue dashed line in Figure 2.6B). We found that the total MPI signal increased linearly with
cell number (r2 = 0.9863) (Figure 2.6C; cell numbers below 8000 were not included as the signal was
deemed “undetectable”). The lowest SNR (above 5) was the sample with 8000 cells (0.01 μg of iron;
SNR of 5.56) and the greatest SNR observed came from the sample with 1.024 million cells (3.67 μg
of iron; SNR of 36.96) (Table 1). The concentration of iron was calculated for each MPI scan by
comparing the amount of signal to the calibration curve shown in Figure 2.5C. The amount of iron was
found to be significantly different for a variety of cell numbers ranging from 8000 to 64000 and 64000
to 1.024 million (Figure 2.6 D/E) (p<0.0001). As excepted, we found that as cell number increased, the
total iron content significantly increased as well.
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Figure 2.6. Cell detection limits for Synomag-D labelled 4T1Br5-TdT-Akaluc cells. (A)
Representative MPI Images for respective cell numbers, where “M” denotes million, and “k” denotes
thousand. White boxes enclose “undetectable signal” (signal below SNR = 5). (B) Maximum MPI
signal for low cell numbers is plotted. Thresholds of 5, and 3 times the standard deviation of the
background noise (SNR 5, SNR 3) are shown in red and blue, respectfully. (C) Total MPI signal was
plotted against the number of cells loaded with Synomag-D to show a positive and linear relationship.
(D, E) Iron mass measured by MPI is significantly different for various cell numbers in the range of 864 x103 cells (D), and 64-1024 x103 cells (E).
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Table 2.1:

Table 2.1: Cell detection limits for Synomag-D labelled 4T1Br5-TdT-Akaluc cells. A dilution of
Synomag-D loaded cells ranging from 1.024 million to 500 was done. Average SNR calculated by
dividing the average mean signal from 3 replicates by the standard deviation of an empty bed (0.366).
SNR below 5 is undetectable based on the Rose Criterion and is not shown. Total Iron Content calculated
by dividing the total MPI signal (n=3) by the slope of the calibration curve shown in Figure 2.6C (6772).
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2.3.6 In Vivo Imaging of Primary Tumours
4T1Br5-TdT-Akaluc cells were injected into the MFP of nude mice (n=4) and monitored with in vivo
MPI and BLI over a period of two weeks. Nude mice were used instead of immunocompetent mice to
avoid any potential immunogenicity problems arising from Akaluc expression. Signal appeared to be
localized to the left MFP on both imaging modalities, which was the site of primary tumour
inoculation. Alignment of images was done by acquiring brightfield images on both modalities, as
shown in Figure 2.7A. MPI scans were then flipped horizontally as they were acquired in prone
position while BLI was performed in supine position. MPI signal was detected in the left MFP of all
mice on days 1 (846.24 ± 210.55A.U.), 8 (579.35 ± 134.88 A.U.) and 14 (508.94 ± 106.23 A.U.)
(Figure 2.7A; left column), with significant decrease in signal and corresponding iron content detected
between days 1 and 14 (p < 0.05) (Figure 2.7B, C). BLI signal was also detected in the left MFP of all
mice on days 0 (7.31x106 ± 1.59x106 P/s), 6 (9.25x107 ± 5.92x107 P/s) and 13 (2.93x108 ± 1.84x108
P/s) (Figure 2.7 A; right column) with a significant increase in BLI signal observed between days 0
and 13 (p < 0.05) (Figure 2.7D).
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Figure 2.7:
A.

B.

C.
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Figure 2.7. Dual Akaluc BLI and MPI for tracking transplanted Synomag-D labelled
D.
4T1Br5 cells in vivo. Representative in vivo BLI and MPI scans (A) are shown for days 0/1,
6/8, and 13/14 post MFP injection of labelled cells. Anatomical left and right are denoted by
“L” and “R” Bright field images used to localize MPI signal in respect to BLI signal. MPI signal
in Arbitrary units (A.U.) enclosed by red circles. BLI displayed as photon flux (P/s). Total MPI
(B), average iron content (calculated by dividing MPI signal by the slope of the 3D calibration
line) (C) and Average BLI signal (D) were all plotted with respect to days post initial injection.
Individual mice are colour coded to aid trend observation. Pairwise comparisons were done for
(B), (C), and (D), showing significant differences in signal over time.
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2.3.7 In Vivo Imaging of Spontaneous Metastases
On day 14, MPI signal was detected at secondary sites throughout the body in all four mice (Figure
2.8A,B). All signals had an SNR of 5 or greater suggesting the distant MPI signal observed was true
signal and not background. It is possible that these signals were the result of iron-labeled metastatic
cancer cells. The locations of distant signal included the right footpad, the epigastric region and the
right middle abdominal quadrant, although no two mice had metastases in the exact same location
(Figure 2.8A,B). A representative image of a mouse with distant MPI signal in the right middle
abdominal region on the contralateral side is shown in Figure 2.9B. In order to visualize this distant
MPI signal a lower window level was needed. Primary signal highlighted in figure 8A is presented in
the standard full dynamic range, corresponding to a max window level of 1.08. In comparison, the
secondary lesion shown in figure 2.8B is presented with a max window level of 0.01.
BLI signal was also detected at secondary sites in 3 of the 4 mice (Figure 2.8C,D) on day 13 by
covering the lower abdomen of the animal (Figure 2.8E,G). This blocked a large portion of the signal
coming from the primary tumour, allowing for longer exposure times and thus, smaller signals to be
visualized. Without this, the strong primary signal masks any other signals that may be present in the
mice (Figure 2.8D). A representative mouse with secondary signal observed in the upper right
abdomen can be seen in Figure 2.9E. Two other mice showed BLI signal in the region of the ipsilateral
armpit, and one mouse showed BLI signal in the contralateral armpit (Figure 2.8CD). Overlaying the
MPI and BLI scans allowed for comparison of signal location between both modalities (Figure 2.8F)
with distinct MPI and BLI signal regions noted.

80
Figure 2.8:
A.
0

A.U.

B.

0.01

L

R

0

A.U.

L

0.01

R

0

A.U.

L

0.01

R

0

A.U.

L

0.01

R

M4

M2
M1

M3

C.
0

R

4

x10 P/s

5

L

0

R

4

x10 P/s

5

0

L

R

4

x10 P/s

5

L

0

R

4

x10 P/s

5

D.
D.

L

Figure 2.8. All secondary signals observed in MPI and Akaluc BLI in vivo. (A) MPI
signals, separate from the primary signal are enclosed by red circles. Scans were overlayed
on a bright field image for anatomical reference. (B) Quantification of secondary signals
from each mouse, with M denoting mouse, followed by a number (M1, M2, M3, M4). (C)
Akaluc BLI signals separate from the primary signal. A dark covering was taped to the
bottom half of each mouse to prevent signal saturation. This allowed for visualization of the
secondary signals as circled in red. (D) Quantification of secondary signals from each mouse.
Mouse 2 had two secondary signals (M-2a, M-2b) while mouse 4 had no secondary signals.
The signal observed for mouse 4 was due to scattering.
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Figure 2.9:
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Figure 2.9. In vivo MPI and Akaluc BLI signal in distant regions. All images are from the
same representative mouse on day 13/14. The left and right of the mouse are marked by “L” and
“R” The MPI scan in (A) is windowed to the full dynamic range, while (B) is the same scan set
to a lower window level. This allows visualization of a secondary signal location, marked by the
red circle. A histogram (C) was made by drawing a line through both the primary and secondary
signal locations in (B) and plotting signal intensity relative to location. Two distinct peaks can
be observed indicating that the signals are indeed separate. BLI of the primary tumour signal
(D) is the same image as seen in Figure 2.7. A dark covering was taped to the bottom half of the
mouse in (E) to prevent signal saturation. This allowed for visualization of the secondary
metastasis as circled in red. An overlay of MPI and BLI scans (G) allows for comparison of
signal location anatomically. MPI signal was flipped to align with BLI scans.
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2.3.8 Ex vivo Histology for transduced TdTomato-Akaluc reporter
Post sacrification, a representative mouse was assessed for the expression of TdTomato and SynomagD in tissues. The presence of TdT (red) was determined through fluorescence microscopy using a
DAPI (blue) counterstain. Cells expressing DAPI are seen in Figure 2.10A, D, G, J. Cells expressing
TdT are represented by Figure 2.10B, E, H, K. An overlay of DAPI and TdT are presented in Figure
2.10C, F, I, L. Virtually all cells from the primary tumour were positive for both DAPI, and TdT,
highlighted by the high level of signal overlap (Fig 2.10 A-F). Sections from the axillary lymph node
which had displayed BLI signal during in vivo experiments exhibit a small fraction of TdT expressing
cells in comparison to the number of DAPI expressing cells (Figure 2.10G-I), which can be seen more
clearly at 80 X magnification (J-L). Some areas of the lymph node did not express TdT at all.

2.3.9 Ex vivo Analysis of the MPI reporter Synomag-D
The presence of Synomag-D in the tumour and lymph node was assessed using a 2D MPI scan, and
through a PPB stain of the sectioned tissues. MPI signal was produced from the primary tumour
(Figure 2.11A), but not from the lymph node (not shown). A PPB stain (Figure 2.11B) of sectioned
tissues further confirmed the presence of iron (blue), in the primary tumour but not in the lymph node.
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Figure 2.10. Ex vivo fluorescence microscopy of primary tumour and axillary lymph node.
Representative histology from one mouse, after tissue perfusion. DAPI (blue) stains all cell nuclei
(A,D,G,J). Florescence in the TdTomato (red) channel, confirms expression of the transduced reporter
(B, E, H, K). An overlay of DAPI and TdTomato was done to compare expression (C,F,I,L). Sections
are shown at both 10 X (A-C,G-I) and 8 X (D-F,J-L) magnification. All cells of the primary tumour (AF) were positive for TdTomato. A small fraction of cells in the lymph node were positive for TdTomato
(G-L). All images taken on an ECHO Resolve microscope.

84
Figure 2.11:
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Figure 2.11. Ex vivo analysis of primary tumour for the MPI reporter Synomag-D. 2D MPI of
excised primary tumour (A), highlights that Synomag-D was present in the tumour. A representative
PPB stain is displayed for one section of the primary tumour. Iron (blue) can be seen amongst the pink
cancer cells, further confirming the presence of Synomag-D within the primary tumour. White arrows
point to two examples of iron present in the tumour. Image of slide taken on an ECHO Resolve
microscope.
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2.4 Discussion
With the ever-increasing prevalence of metastatic cancer deaths (3), there is an urgent need for highly
sensitive imaging technologies that can noninvasively visualize and quantify tumour burden in
preclinical cancer models. Iron-based cellular MRI has historically been one of the most widely used
techniques for tracking the fate and biodistribution of cancer cells in vivo (11-14), however, the
indirect detection of SPIO through signal blooming, makes quantifying cell number difficult (16).
Alternatively, MPI, a new player in the field of cell tracking, can directly detect SPIO labeled cells
allowing for quantitative hotspot imaging (22,23), although the sensitivity is not yet on par with
cellular MRI, and in vivo resolution has been an ongoing problem. BLI, has often been paired with
MRI or MPI, due to its ability to reliably track both proliferation and viability, something not possible
with probe-based modalities. BLI has been traditionally limited its low depth penetration, however, the
development of Akaluc, and Akalumine, a NIR BLI reporter system, greatly mitigates this. Akaluc BLI
has been shown to offer lower signal attenuation, superior depth penetration, and higher sensitivity for
small animal imaging compared to the traditional luciferase reporter systems (51-53).
This is the first study to combine MPI and Akaluc BLI for quantitative, high sensitivity tracking of
metastatic cancer cells in a preclinical breast cancer model. We believe the implementation of this
strategy will be extremely valuable in studying the underlying mechanisms of cancer metastasis as well
as provide the imaging framework to more accurately evaluate therapeutic efficacy in vivo during the
development of new anti-cancer agents.
Several groups have previously demonstrated the ability of MPI to track cancer cells, however few
have combined MPI with an optical imaging technique, and none have combined it with Akaluc BLI.
Yu et al., in 2017, became the first group to visualize cancer cells in vivo with MPI when they tracked
the uptake of IV administered MPI nanoparticles by a subcutaneous breast cancer tumour via the EPR
effect (27). BLI was used on day 1, as a positive control for cell location. In 2018, both Song et al., and
Jung et al., tracked MPI cancer cells labelled with MPI nanoparticles expressing fluorescent moieties.
However, by using fluorescent moieties, rather than a fluorescent reporter gene, this method did not
allow for visualization of proliferation or viability (32,55). Parkins et al., in 2020, tracked circulating
tumour cells with MPI, however no optical imaging system was used (56). Later in 2020, Melo et al.,
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used MPI to track the metastasis of cancer cells to the brain of mice (57). In 2021, Knier et al., tracked
patient derived xenografts with both MPI and BLI, however the same mice were not imaged on both
modalities (58). Makela et al., in 2021, used MPI and Red-Fluc BLI to track 4T1 cell implantation,
tumour growth, and the subsequent spontaneous metastasis to the lymph node. However, BLI signal
was not quantified (59). Based on the emission spectra of Red-Fluc and Akaluc BLI, Akaluc should
have far superior depth penetration and sensitivity in vivo.
While the literature on the implementation of Akaluc BLI for cancer cell tracking is sparse, this system
has demonstrated the ability to sensitively track both tumour burden and metastasis, although it has yet
to be paired with MPI. In 2018, Iwano et al., were able to detect single Akaluc expressing cells
implanted in the lungs of mice, mimicking metastasis to one of the deepest regions (53). In 2021, both
Liu et al., and Ichise et al., tracked spontaneous lung metastases in vivo using MPI (60,61).
Additionally, the treatment of these metastases by NK cells was evaluated in the Ichise paper,
however, at the time of writing this has yet to be peer reviewed (61).
Here, for the first time, we were able to detect and quantify cancer cells in the same mouse using MPI
and Akaluc BLI. There was high concordance between the location of MPI and BLI signal at early
time points, indicating that the same cell populations were being imaged on both modalities.
Additionally, there was no observable background signal in the gut for either MPI or Akaluc BLI. A
reoccurring problem in MPI is a gut signal caused by contamination of food and bedding (62,63),
however by fasting as well as the removal of bedding prior to imaging, this was mitigated. Removing
this background signal allows for the detection of cells in regions that may have otherwise been hidden
such as in the lower abdomen. Additionally, several sources have reported background liver signal
with Akalumine, in the absence of Akaluc (27,64), however, this was not observed for this experiment.
By the experimental endpoint, MPI and BLI signal differed greatly. MPI signal decreased by roughly
40% by day 14, suggesting probe dilution because of highly proliferative cells losing their iron label
through cell division. Interestingly, this drop in signal occurred at a far more rapid rate than what was
previously reported by Song et al., in 2018. In that paper, MPI signal only decreased by 20% over a
20-day span (32). This increased rate in signal loss may suggest that for highly proliferative cell lines,
MPI may not be a reliable tool for long-term quantification of cells. In contrast, the BLI signal
observed on day 13 was more than a 28-fold increase from the signal detected on day 1, which was
expected as primary tumours grew. These inversed trends between MPI and BLI data match the results
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reported by Knier et al., and Makela et al., in 2021 and demonstrates that BLI can provide information
on cell proliferation for future MPI studies (58,59).
Additionally, by the experimental endpoint, both MPI and BLI were able to detect signal from regions
outside of the primary MFP tumour. These signals are possibly a result of metastases. Both BLI and
MPI have previously demonstrated the ability to detect metastases in mice (53,57,59,60), however, in
this study, MPI was able to detect iron signal that was covered up during our BLI metastases imaging
protocol. Specifically, Akaluc BLI was able to detect signal in distal regions such as the armpit or
upper gut, however, doing so required covering the primary tumour. MPI signal was not detected in
these distant lesions. This was likely due to the dilution of tracer minimizing the amount of iron
present within the cells that seeded the metastasis. The ex vivo histology supports this theory, as no
iron was detected in a lymph node which was positive for BLI signal and negative for MPI signal in
vivo. However, MPI signal was detectable in more proximal regions to the primary tumours, as no
covering was needed. Although no histology was done to confirm that these were metastases, a line
plot through the primary tumour and the secondary lesion revealed two distinct signal peaks, indicating
that this secondary signal was not associated with the primary tumour. The discrepancy between
secondary locations observed through MPI and BLI highlight the benefits of using both modalities to
give a more complete picture of cancer cell fate in this spontaneous metastasis model. The use of a
single modality may result in missing critical information, hindering the true assessment of disease
progression.
While the sensitivity of Akaluc as a BLI reporter gene has been well established, it is important to also
consider the added sensitivity of Synomag-D for MPI cell tracking. In concurrence with Vogel et al.,
2021 and Sehl et al., 2020, we found that Synomag-D was nearly 4 times as sensitive as the standard
Vivotrax, with a similar resolution for detecting particles in vitro (21,30). This reflects an in vivo
detection limit of 0.01 μg of iron or approximately 8000 cells. In a similar experiment by our lab, as
few as 4000 Synomag-D labelled dendritic cells could be detected in vivo, corresponding to an iron
volume of 0.02 μg. The discrepancy in values can be attributed to the concentration of iron present
within each cell (2.18 ± 0.8 pg/cell vs. 5.5 pg/cell) (63). Unlike many immune cells, cancer cells are
not naturally phagocytic. This makes labelling cancer cells with high concentrations of iron difficult
and may limit the sensitivity future MPI cancer cell tracking experiments. MPI has not yet reached the
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single cell sensitivity that is possible with MRI or Akaluc BLI however, advancements in tailored MPI
tracers and imaging techniques will soon allow for detection of smaller metastases at earlier
timepoints. Additionally, our study provides evidence that labeling cells with Synomag-D has no
significant effects on cell viability or BLI signal. These findings are encouraging for the potential
clinical use of Synomag-D as an MPI tracer for additional studies.
MPI studies are often limited by the dilution of MPI tracer over time, as well as bystander cell labeling
(11-13,34,65). By adding complementary Akaluc-BLI to our MPI study, this was no longer a concern,
however there are still a few limitations to be considered. First, while the in vivo results are promising,
a small sample size was used. Future studies should be conducted to assess the reproducibility of these
findings as well as explore other imaging time points. Second, due to the potential stress of isoflurane
anaesthesia, MPI and BLI were performed on different days, which limited the comparison that could
be made between the two modalities. Additionally, mice were imaged in the prone position for MPI,
and the supine position for MPI. Images needed to be flipped horizontally, before the signals could be
aligned. Quantification of MPI signal provides its own challenges. While the primary and secondary
signal locations were distinct from one another, the tails of each signal overlapped to some degree, as
seen in the histogram (Figure 2.8C). As a result, the exact quantification of secondary lesions is
unlikely. Finally, no histology was done for MPI positive secondary lesions, which prevented us from
confirming that these were in fact metastases. By the time the BLI and MPI signals were aligned,
tissues had already been collected for ex vivo analysis, and we were unaware that the signals originated
from different locations. A faster pipeline of aligning the images at endpoint will hopefully prevent this
from happening in the future.
In this study, we demonstrated for the first time the ability to track metastatic cancer cells in vivo with
both MPI and Akaluc BLI. As highlighted by the differences in secondary metastasis detection, MPI
and BLI provide complementary information on cell fate, which will provide a more complete picture
on the intricacies of cancer metastasis. In this study, breast cancer cells are the first and only cell type
of any kind to be tracked with this multimodal imaging approach. Future experiments will use this
framework to track both proliferative and non-proliferative cell populations including other cancers,
stem cells and immune cells. Specifically, we hope to use this model to track the delivery and
therapeutic effect of cellular therapies such as CAR-T or NK cells, the former which has already begun
separately with both modalities (66,67). Additionally, in the future, MPI may be combined with other
reporter gene modalities that are clinically relevant such as PET

89

2.5 References
1. Dillekås, H., Rogers, M. S., & Straume, O. (2019). Are 90% of deaths from cancer caused by
metastases? Cancer Medicine, 8(12), 5574–5576.
https://doi.org/https://doi.org/10.1002/cam4.2474
2. Patanaphan, V., Salazar, O. M., & Risco, R. (1988). Breast cancer: metastatic patterns and their
prognosis. Southern medical journal, 81(9), 1109–1112.
3. Cagan, R., & Meyer, P. (2017). Rethinking cancer: current challenges and opportunities in cancer
research. Disease models & mechanisms, 10(4), 349–352. https://doi.org/10.1242/dmm.030007
4. Condeelis, J., & Weissleder, R. (2010). In vivo imaging in cancer. Cold Spring Harbor perspectives
in biology, 2(12), a003848. https://doi.org/10.1101/cshperspect.a003848
5. Bulte, J. W., & Kraitchman, D. L. (2004). Iron oxide MR contrast agents for molecular and cellular
imaging. NMR in biomedicine, 17(7), 484–499. https://doi.org/10.1002/nbm.924
6. Frank, J. A., Zywicke, H., Jordan, E. K., Mitchell, J., Lewis, B. K., Miller, B., Bryant, L. H., Jr, &
Bulte, J. W. (2002). Magnetic intracellular labeling of mammalian cells by combining (FDAapproved) superparamagnetic iron oxide MR contrast agents and commonly used transfection
agents. Academic radiology, 9 Suppl 2, S484–S487. https://doi.org/10.1016/s10766332(03)80271-4
7. Frank, J. A., Miller, B. R., Arbab, A. S., Zywicke, H. A., Jordan, E. K., Lewis, B. K., Bryant, L. H.,
Jr, & Bulte, J. W. (2003). Clinically applicable labeling of mammalian and stem cells by
combining superparamagnetic iron oxides and transfection agents. Radiology, 228(2), 480–487.
https://doi.org/10.1148/radiol.2281020638
8. Yurt, A., & Kazancı, N. (2008). Investigation of magnetic properties of various complexes prepared
as contrast agents for MRI. Journal of Molecular Structure, 892(1), 392–397.
https://doi.org/https://doi.org/10.1016/j.molstruc.2008.06.024
9. Shokrollahi, H. (2013). Contrast agents for MRI. Materials Science and Engineering: C, 33(8),
4485–4497. https://doi.org/https://doi.org/10.1016/j.msec.2013.07.012
10. Hinds, K. A., Hill, J. M., Shapiro, E. M., Laukkanen, M. O., Silva, A. C., Combs, C. A., Varney, T.
R., Balaban, R. S., Koretsky, A. P., & Dunbar, C. E. (2003). Highly efficient endosomal
labeling of progenitor and stem cells with large magnetic particles allows magnetic resonance
imaging of single cells. Blood, 102(3), 867–872. https://doi.org/10.1182/blood-2002-12-3669
11. Heyn, C., Ronald, J. A., Mackenzie, L. T., MacDonald, I. C., Chambers, A. F., Rutt, B. K., &
Foster, P. J. (2006). In vivo magnetic resonance imaging of single cells in mouse brain with
optical validation. Magnetic resonance in medicine, 55(1), 23–29.
https://doi.org/10.1002/mrm.20747

90
12. Heyn, C., Ronald, J. A., Ramadan, S. S., Snir, J. A., Barry, A. M., MacKenzie, L. T., Mikulis, D.
J., Palmieri, D., Bronder, J. L., Steeg, P. S., Yoneda, T., MacDonald, I. C., Chambers, A. F.,
Rutt, B. K., & Foster, P. J. (2006). In vivo MRI of cancer cell fate at the single-cell level in a
mouse model of breast cancer metastasis to the brain. Magnetic resonance in medicine, 56(5),
1001–1010. https://doi.org/10.1002/mrm.21029
13. Foster, P. J., Dunn, E. A., Karl, K. E., Snir, J. A., Nycz, C. M., Harvey, A. J., & Pettis, R. J. (2008).
Cellular magnetic resonance imaging: in vivo imaging of melanoma cells in lymph nodes of
mice. Neoplasia (New York, N.Y.), 10(3), 207–216. https://doi.org/10.1593/neo.07937
14. Shapiro, E.M., Sharer, K., Skrtic, S. and Koretsky, A.P. (2006), In vivo detection of single cells by
MRI. Magnetic Resonance in Medicine, 55: 242-249. https://doi.org/10.1002/mrm.20718
15. Shapiro, E. M., Medford-Davis, L. N., Fahmy, T. M., Dunbar, C. E., & Koretsky, A. P. (2007).
Antibody-mediated cell labeling of peripheral T cells with micron-sized iron oxide particles
(MPIOs) allows single cell detection by MRI. Contrast media & molecular imaging, 2(3), 147–
153. https://doi.org/10.1002/cmmi.134
16. Liu, W., Dahnke, H., Jordan, E. K., Schaeffter, T., & Frank, J. A. (2008). In vivo MRI using
positive-contrast techniques in detection of cells labeled with superparamagnetic iron oxide
nanoparticles. NMR in Biomedicine, 21(3), 242–250.
https://doi.org/https://doi.org/10.1002/nbm.1187
17. Shetty, A. S., Sipe, A. L., Zulfiqar, M., Tsai, R., Raptis, D. A., Raptis, C. A., & Bhalla, S. (2019).
In-phase and opposed-phase imaging: Applications of chemical shift and magnetic
susceptibility in the chest and abdomen. Radiographics, 39(1), 115–135.
https://doi.org/10.1148/rg.2019180043
18. Liu, W., & Frank, J. A. (2009). Detection and quantification of magnetically labeled cells by
cellular MRI. European journal of radiology, 70(2), 258–264.
https://doi.org/10.1016/j.ejrad.2008.09.021
19. Cromer Berman, S. M., Walczak, P., & Bulte, J. W. M. (2011). Tracking stem cells using magnetic
nanoparticles. WIREs Nanomedicine and Nanobiotechnology, 3(4), 343–355.
https://doi.org/https://doi.org/10.1002/wnan.140
20. Bulte, J. W., Walczak, P., Janowski, M., Krishnan, K. M., Arami, H., Halkola, A., Gleich, B., &
Rahmer, J. (2015). Quantitative "Hot Spot" Imaging of Transplanted Stem Cells using
Superparamagnetic Tracers and Magnetic Particle Imaging (MPI). Tomography (Ann Arbor,
Mich.), 1(2), 91–97. https://doi.org/10.18383/j.tom.2015.00172
21. Sehl, O. C., Gevaert, J. J., Melo, K. P., Knier, N. N., & Foster, P. J. (2020). A perspective on cell
tracking with magnetic particle imaging. Tomography, 6(4), 315–324.
https://doi.org/10.18383/j.tom.2020.00043
22. Gleich, B. (2001). Verfahren zur Ermittlung der räumlichen Verteilung magnetischer
Partikel. German Patent DE-10151778-A1.
23. Gleich, B., & Weizenecker, J. (2005). Tomographic imaging using the nonlinear response of
magnetic particles. Nature, 435(7046), 1214–1217. https://doi.org/10.1038/nature03808

91
24. Wu, L. C., Zhang, Y., Steinberg, G., Qu, H., Huang, S., Cheng, M., Bliss, T., Du, F., Rao, J., Song,
G., Pisani, L., Doyle, T., Conolly, S., Krishnan, K., Grant, G., & Wintermark, M. (2019). A
Review of Magnetic Particle Imaging and Perspectives on Neuroimaging. AJNR. American
journal of neuroradiology, 40(2), 206–212. https://doi.org/10.3174/ajnr.A5896
25. Saritas, E. U., Goodwill, P. W., Croft, L. R., Konkle, J. J., Lu, K., Zheng, B., & Conolly, S. M.
(2013). Magnetic particle imaging (MPI) for NMR and MRI researchers. Journal of magnetic
resonance (San Diego, Calif. : 1997), 229, 116–126. https://doi.org/10.1016/j.jmr.2012.11.029
26. Zheng, B., Yu, E., Orendorff, R., Lu, K., Konkle, J. J., Tay, Z. W., Hensley, D., Zhou, X. Y.,
Chandrasekharan, P., Saritas, E. U., Goodwill, P. W., Hazle, J. D., & Conolly, S. M. (2017).
Seeing SPIOs Directly In Vivo with Magnetic Particle Imaging. Molecular imaging and
biology, 19(3), 385–390. https://doi.org/10.1007/s11307-017-1081-y
27. Yu, E. Y., Bishop, M., Zheng, B., Ferguson, R. M., Khandhar, A. P., Kemp, S. J., Krishnan, K. M.,
Goodwill, P. W., & Conolly, S. M. (2017). Magnetic Particle Imaging: A Novel in Vivo
Imaging Platform for Cancer Detection. Nano letters, 17(3), 1648–1654.
https://doi.org/10.1021/acs.nanolett.6b04865
28. Talebloo, N., Gudi, M., Robertson, N., & Wang, P. (2020). Magnetic Particle Imaging: Current
Applications in Biomedical Research. Journal of magnetic resonance imaging, 51(6), 1659–
1668. https://doi.org/10.1002/jmri.26875
29. Grüttner, A., Kowalski, F., Fidler, M., Steinke, F., Westphal, & Teller, H. (2018). Nanoflower
particles: A new tracer for mpi, physical characterization and initial in vitro toxicity studies.
International Workshop on Magnetic Particle Imaging, 17-18.
30. Vogel, P., Kampf, T., Rückert, M. A., Grüttner, C., Kowalski, A., Teller, H., & Behr, V. C. (2021).
Synomag®: The new high-performance tracer for magnetic particle imaging. International
Journal on Magnetic Particle Imaging, 7(1). https://doi.org/10.18416/IJMPI.2021.2103003
31. Zheng, B., Vazin, T., Goodwill, P. W., Conway, A., Verma, A., Saritas, E. U., Schaffer, D., &
Conolly, S. M. (2015). Magnetic Particle Imaging tracks the long-term fate of in vivo neural
cell implants with high image contrast. Scientific reports, 5, 14055.
https://doi.org/10.1038/srep14055
32. Song, G., Chen, M., Zhang, Y., Cui, L., Qu, H., Zheng, X., Wintermark, M., Liu, Z., & Rao, J.
(2018). Janus Iron Oxides @ Semiconducting Polymer Nanoparticle Tracer for Cell Tracking
by Magnetic Particle Imaging. Nano letters, 18(1), 182–189.
https://doi.org/10.1021/acs.nanolett.7b03829
33. Tay, Z. W., Savliwala, S., Hensley, D. W., Fung, K. L. B., Colson, C., Fellows, B. D., Zhou, X.,
Huynh, Q., Lu, Y., Zheng, B., Chandrasekharan, P., Rivera-Jimenez, S. M., Rinaldi-Ramos, C.
M., & Conolly, S. M. (2021). Superferromagnetic Nanoparticles Enable Order-of-Magnitude

92
Resolution & Sensitivity Gain in Magnetic Particle Imaging. Small Methods, 2100796.
https://doi.org/https://doi.org/10.1002/smtd.202100796
34. Amsalem, Y., Mardor, Y., Feinberg, M. S., Landa, N., Miller, L., Daniels, D., Ocherashvilli, A.,
Holbova, R., Yosef, O., Barbash, I. M., & Leor, J. (2007). Iron-oxide labeling and outcome of
transplanted mesenchymal stem cells in the infarcted myocardium. Circulation, 116(11 Suppl),
I38–I45. https://doi.org/10.1161/CIRCULATIONAHA.106.680231
35. Alsawaftah, N., Farooq, A., Dhou, S., & Majdalawieh, A. F. (2021). Bioluminescence Imaging
Applications in Cancer: A Comprehensive Review. IEEE reviews in biomedical
engineering, 14, 307–326. https://doi.org/10.1109/RBME.2020.2995124
36. Bu, L., Ma, X., Tu, Y., Shen, B., & Cheng, Z. (2013). Optical image-guided cancer
therapy. Current pharmaceutical biotechnology, 14(8), 723–732.
https://doi.org/10.2174/1389201014666131226112507
37. Söling, A., & Rainov, N. G. (2003). Bioluminescence imaging in vivo - application to cancer
research. Expert opinion on biological therapy, 3(7), 1163–1172.
https://doi.org/10.1517/14712598.3.7.1163
38. Edinger, M., Sweeney, T. J., Tucker, A. A., Olomu, A. B., Negrin, R. S., & Contag, C. H. (1999).
Noninvasive assessment of tumor cell proliferation in animal models. Neoplasia (New York,
N.Y.), 1(4), 303–310. https://doi.org/10.1038/sj.neo.7900048
39. Kozlowski, J. M., Fidler, I. J., Campbell, D., Xu, Z. L., Kaighn, M. E., & Hart, I. R. (1984).
Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer
research, 44(8), 3522–3529.
40. Sweeney, T. J., Mailänder, V., Tucker, A. A., Olomu, A. B., Zhang, W., Cao, Y. a., Negrin, R. S.,
& Contag, C. H. (1999). Visualizing the kinetics of tumor-cell clearance in living
animals. Proceedings of the National Academy of Sciences of the United States of
America, 96(21), 12044–12049. https://doi.org/10.1073/pnas.96.21.12044
41. Bhang, H. E., Gabrielson, K. L., Laterra, J., Fisher, P. B., & Pomper, M. G. (2011). Tumor-specific
imaging through progression elevated gene-3 promoter-driven gene expression. Nature
medicine, 17(1), 123–129. https://doi.org/10.1038/nm.2269
42. Stollfuss, J., Landvogt, N., Abenstein, M., Ziegler, S., Schwaiger, M., Senekowitsch-Schmidtke,
R., & Wieder, H. (2015). Non-invasive imaging of implanted peritoneal carcinomatosis in mice
using PET and bioluminescence imaging. European Journal of Nuclear Medicine and
Molecular Imaging: Research, 5(1), 44. https://doi.org/10.1186/s13550-015-0125-z
43. Kircher, M. F., Gambhir, S. S., & Grimm, J. (2011). Noninvasive cell-tracking methods. Nature
Reviews Clinical Oncology, 8(11), 677–688. https://doi.org/10.1038/nrclinonc.2011.141
44. James, M. L., & Gambhir, S. S. (2012). A molecular imaging primer: Modalities, imaging agents,
and applications. Physiological Reviews, 92(2), 897–965.
https://doi.org/10.1152/physrev.00049.2010
45. Modo, M. (2008). Noninvasive imaging of transplanted cells. Current Opinion in Organ
Transplantation, 13(6), 654–658. https://doi.org/10.1097/MOT.0b013e328317a43c

93
46. Puaux, A.-L., Ong, L. C., Jin, Y., Teh, I., Hong, M., Chow, P. K. H., Golay, X., & Abastado, J.-P.
(2011). A Comparison of Imaging Techniques to Monitor Tumor Growth and Cancer
Progression in Living Animals. International Journal of Molecular Imaging, 2011, 1–12.
https://doi.org/10.1155/2011/321538
47. Sadikot, R. T., & Blackwell, T. S. (2005). Bioluminescence imaging. Proceedings of the American
Thoracic Society, 2(6), 537–512. https://doi.org/10.1513/pats.200507-067DS
48. Welsh, D. K., & Noguchi, T. (2012). Cellular bioluminescence imaging. Cold Spring Harbor
protocols, 2012(8), pdb.top070607. https://doi.org/10.1101/pdb.top070607
49. Yao, Z., Zhang, B. S., & Prescher, J. A. (2018). Advances in bioluminescence imaging: new probes
from old recipes. Current opinion in chemical biology, 45, 148–156.
https://doi.org/10.1016/j.cbpa.2018.05.009
50. Close, D. M., Xu, T., Sayler, G. S., & Ripp, S. (2011). In vivo bioluminescent imaging (BLI):
noninvasive visualization and interrogation of biological processes in living animals. Sensors
(Basel, Switzerland), 11(1), 180–206. https://doi.org/10.3390/s110100180
51. Iwano, S., Obata, R., Miura, C., Kiyama, M., Hama, K., Nakamura, M., ... & Niwa, H. (2013).
Development of simple firefly luciferin analogs emitting blue, green, red, and near-infrared
biological window light. Tetrahedron, 69(19), 3847-3856.
52. Kuchimaru, T., Iwano, S., Kiyama, M., Mitsumata, S., Kadonosono, T., Niwa, H., Maki, S., &
Kizaka-Kondoh, S. (2016). A luciferin analogue generating near-infrared bioluminescence
achieves highly sensitive deep-tissue imaging. Nature Communications, 7(1), 11856.
https://doi.org/10.1038/ncomms11856
53. Iwano, S., Sugiyama, M., Hama, H., Watakabe, A., Hasegawa, N., Kuchimaru, T., Tanaka, K. Z.,
Takahashi, M., Ishida, Y., Hata, J., Shimozono, S., Namiki, K., Fukano, T., Kiyama, M.,
Okano, H., Kizaka-kondoh, S., Mchugh, T. J., Yamamori, T., Hioki, H., … Miyawaki, A.
(2018). Moving Animals. 939(February), 935–939.
54. Rose, A. (1984). Vision: Human and Electronic. Plenum Press.
55. Jung, K. O., Jo, H., Yu, J. H., Gambhir, S. S., & Pratx, G. (2018). Development and MPI tracking
of novel hypoxia-targeted theranostic exosomes. Biomaterials, 177, 139–148.
https://doi.org/10.1016/j.biomaterials.2018.05.048
56. Parkins, K. M., Melo, K. P., Ronald, J. A., & Foster, P. J. (2020). Visualizing tumour self-homing
with magnetic particle imaging. BioRxiv. https://doi.org/10.1101/2020.02.17.953232
57. Melo, K. P., Makela, A. V, Hamilton, A. M., & Foster, P. J. (2020). Development of Magnetic
Particle Imaging (MPI) for Cell Tracking and Detection. BioRxiv.
https://doi.org/10.1101/2020.07.12.197780

94
58. Knier, N. N., & Foster, P. J. (2021). Tracking cancer cells in the mouse brain with magnetic
resonance imaging (MRI) and magnetic particle imaging (MPI). (2021). International Society
for Magnetic Resonance in Medicine. https://www.ismrm.org/21/programfiles/TeaserSlides/TeasersPresentations/1213-Teaser.html
59. Makela, A. V., Schott, M. A., Sehl, O. C, Gevaert, J. J., Foster, P. J., Contag, C. H. (2021).
Tracking the fates of iron-labeled tumor cells in vivo using Magnetic Particle Imaging. BioRxiv.
https://doi.org/10.1101/2021.10.06.463387.
60.Liu, S., Nyström, N. N., Kelly, J. J., Hamilton, A. M., Fu, Y., & Ronald, J. A. (2021). Molecular
Imaging Reveals a High Degree of Cross-Seeding of Spontaneous Metastases in a Novel
Mouse Model of Synchronous Bilateral Breast Cancer. Molecular Imaging and Biology.
https://doi.org/10.1007/s11307-021-01630-z
61. Ichise, H., Tsukamoto, S., Hirashima, T., Konishi, Y., Oki, C., Tsukiji, S., Iwano, S., Miyawaki,
A., Sumiyama, K., Terai, K., & Matsuda, M. (2021). Metastatic Single Tumor Cells Evade NK
Cell-mediated Killing by Thrombin-mediated Loss of the Activating Ligand CD155/PVR/Necl5. BioRxiv.
62. Sehl, O. C., Foster, P. J. (2021). The sensitivity of magnetic particle imaging and fluorine-19
magnetic resonance imaging for cell tracking. BioRxiv,
https://doi.org/10.1101/2021.08.31.458286
63. Gevaert, J. J., Fink, C., Dikeakos, J., Dekaban, G. A., Foster, P. J. (2021). Magnetic Particle
Imaging is a sensitive in vivo imaging modality for the quantification of dendritic cell
migration. BioRxiv, https://doi.org/10.1101/2021.09.22.461401
64. Amadeo, F., Plagge, A., Chacko, A., Wilm, B., Hanson, V., Liptrott, N., Murray, P., & Taylor, A.
(2021). Firefly luciferase offers superior performance to AkaLuc for tracking the fate of
administered cell therapies. European Journal of Nuclear Medicine and Molecular Imaging.
https://doi.org/10.1007/s00259-021-05439-4
65. Makela, A. V., Murrell, D. H., Parkins, K. M., Kara, J., Gaudet, J. M., & Foster, P. J. (2016).
Cellular imaging with MRI. Topics in Magnetic Resonance Imaging, 25(5), 177–186.
https://doi.org/10.1097/RMR.0000000000000101
66. Su, Y., Walker, J., Park, Y., Smith, T., Liu, L., Hall, M., Labanieh, L., Hurst, R., Wang, D., Encell,
L., Kim, N., Zhang, F., Kay, M., Casey, K., Majzner, R., Cochran, J., Mackall, C., Kirkland, T.,
& Lin, M. (2020). Novel NanoLuc substrates enable bright two-population bioluminescence
imaging in animals. Nature Methods, 17, 1–9. https://doi.org/10.1038/s41592-020-0889-6
67. Rivera-Rodriguez, A., Hoang-Minh, L. B., Chiu-Lam, A., Sarna, N., Marrero-Morales, L.,
Mitchell, D. A., & Rinaldi-Ramos, C. M. (2021). Tracking adoptive t cell immunotherapy using
magnetic particle imaging. Nanotheranostics, 5(4), 431–444.
https://doi.org/10.7150/ntno.55165

95

Chapter 3
This chapter serves to summarize the findings presented in this thesis, as well as to highlight
limitations and future work.

3.1 Chapter 2 Summary and Discussion
The experiments conducted in this thesis were done with the overarching goal of developing a
multimodal preclinical imaging system for quantitative and sensitive tracking of breast cancer cells in
vivo. MPI and Akaluc BLI were chosen as our core imaging modalities as we believe their individual
characteristics could complement one another to give a more complete picture of cell fate and
biodistribution. MPI offers remarkable specificity, positive hotspot imaging, and the ability to quantify
cells based on the concentration of iron within them, all without the use of radiation. Additionally,
there are no depth effects associated with MPI, allowing for deep tissue imaging (1-8). Despite these
advantageous characteristics, MPI is limited by poor spatial resolution (9), and limited sensitivity
compared to other modalities such as MRI (10-15). Additionally, being a probe-based system, MPI
cannot provide a measure of cell viability or proliferation for dividing cell populations over time (1217).
BLI on the other hand is an optical imaging system, often used as a marker for cell viability and
proliferation over long durations (18-25). Due to light attenuation by tissues, traditional FLuc BLI is
limited by depth effects, low 3D spatial resolution, and low sensitivity for deeply situated tissues
(18,26-29). Akaluc BLI utilizes NIR light, which has lower attenuation in biological tissue. This has
allowed for single cell sensitivity for deeply situated cells (30-32).
Our work successfully combined these two modalities, demonstrating for the first time, the ability to
track transplanted cells with MPI and Akaluc BLI. Dual labelled (Akaluc and the SPIO Synomag-D),
implanted into the mammary fat pad of nude mice were visualized and quantified on MPI and Akaluc
BLI over a 2-week period. The location of the signal for both MPI and Akaluc BLI corresponded to the
location of the primary tumour (as confirmed through ex vivo histology), indicating successful cell
implantation. From Day 1 to day 14, the MPI signal decreased by 40%, corresponding to a 1.57 μg
decrease in iron content. This can likely be attributed to a combination of cell proliferation, dispersion,
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and clearance. The continued decrease in signal may suggest that MPI cannot be used to indefinitely
track proliferating cell populations, especially for experiments where lower cell numbers are initially
implanted. Conversely, the signal produced in Akaluc BLI increased by orders of magnitude over the
course of the experiment (28-fold increase), demonstrating the ability of Akaluc BLI to track rapid cell
proliferation in cancer models.
Secondary signals, separate from the primary tumour were observed on day 13/14 of this experiment
on both Akaluc BLI and MPI. It is possible that these secondary signals corresponded to metastases, as
highlighted by the ex vivo histology of a BLI positive lymph node. What was interesting about these
findings was that when the Akaluc BLI and MPI scans were overlayed it was clear that the same
secondary signal locations were not seen on Akaluc BLI and MPI. Instead, each modality was able to
visualize completely unique cell locations. Akaluc BLI detected signal from mice in the ipsilateral and
contralateral armpits, as well as the upper mid right abdomen. A major limitation in the detection of
these signals, however, was that a dark covering was needed to prevent camera saturation by the
intense primary tumour. This prevented visualization of regions in the lower half of the mouse, close to
the primary tumour. MPI detected signals from the right footpad, the epigastric region, and the right
middle abdominal quadrant.
For a few reasons, we believe that Akaluc BLI may be more sensitive than MPI for detection of
potential metastases. First, literature has demonstrated that Akaluc BLI has single cell sensitivity in
vivo (32), while the highest reported sensitivity for MPI is 200-250 cells (33,34). Second, by the time
secondary lesions form, multiple cell passages have already occurred, resulting in dilution of SPIO.
Based on this, it is possible that cells seeding the secondary lesion fall below the threshold for
detection. Further, when Akaluc transduced cells seed a metastasis, their continued proliferation will
increase the BLI signal in the tissue. This theory is supported by the ex vivo histology, in which cells of
the metastatic lymph node were positive for the transduced reporter construct but did not contain
detectable iron. The increased sensitivity resulting from these factors allowed Akaluc BLI to detect
signal from regions distal to the primary tumour, however, due to the required shielding Akaluc BLI
could not detect potential metastases proximal to the primary tumour. No shielding was required for
MPI allowing the visualization of proximal lesions, previously covered for BLI. These findings give
credence to the belief that combining imaging modalities, in this case Akaluc BLI and MPI can give a
more complete picture of cell fate. By limiting research to a single modality, researchers run the risk of
missing important information due to limitations inherent to the modality.
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A key aspect of MPI is that iron content is directly and linearly quantitative based on generated signal.
This allows us to calculate the amount of iron present in a region based on the signal it produces (2-8).
In order to do this, calibration lines were made for all scan modes used in the experiment. The slopes
of these lines can then be used to calculate unknown iron concentration. This method was used for both
the in vivo experiments listed above, as well as for determining an in vitro detection limit of 8000
Synomag-D labelled cells with a 3D scan. This limit was possible due to nearly 4-fold increase in
sensitivity offered by Synomag-D in comparison to Vivotrax, as shown by the relaxometry data. While
more sensitive than Vivotrax, other MPI tracers have shown higher sensitivity which could be used to
improve dual tracking with MPI and Akaluc BLI (34,35).

3.2 Challenges and Limitations of MPI
3.2.1 Contamination
The MPI system can easily become contaminated due to the presence of iron in a variety of common
lab materials. Examples of this includes residual iron from dust, scissor cuts, paper towels, dirt from
shoes, and specific tapes. If this iron contaminates the bore or bed of the MPI, it can result in signal,
causing unwanted hotspots, or a higher-than-average background signal. As the SNR of an image is
calculated using the background of an empty bed scan, contamination will decrease the cell detection
sensitivity of MPI. Early on during my MPI experiments, our lab had a contamination problem which
made any data collected at that time unusable. In vitro calibration, and cell detection experiments
needed to be repeated before a solution was found to the contamination issue.
Our lab has introduced protocols to minimize the amount of contamination present. A plastic shield has
been installed to cover the bore of the MPI. This covering is left on at all times unless a scan is being
conducted. Secondly beds are cleaned with 70% ethanol prior to use and wiped down thoroughly with
Kimwipes. A compressed air hose was installed to the wall of the MPI use to blow out any serious
contaminants inside the bore, or on the bed. All lab surfaces, equipment, and floors are regularly
cleaned to minimize dust and dirt build up. These protocols have significantly reduced the amount and
frequency of contamination.
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3.2.2 Unwanted sources of signal
Mice scanned with MPI occasionally show a large gastrointestinal signal, even in the absence of an
injected tracer. We have concluded that this is due iron present in mouse feed, and some beddings.
This is especially concerning when trying to quantify low cell numbers or looking at an area close to
the gut region. Our lab has minimized this limitation by fasting mice for 12 hours prior to scanning, as
well as replacing bedding with a corn-based alternative, as described by Gevaert et al., in 2021 (36).
This technique was used in this thesis, and.as a result gut signal fell below the threshold of detection,
although it is possible that small traces of this contamination remain.

3.2.3 MPI hardware failure
In March of 2021, a resistor for the x transmit channel had to be replaced. This hardware failed due to
overheating. This occurred during my 3D Calibration experiment, resulting in all acquired data to be
unusable. Data for the 3D calibration line had to be recollected on a later date. To avoid this problem
in the future it was advised that the MPI system should not be in operation for more than 5 hours at a
time. After this time, a 2 hour cool down period is needed to ensure that no hardware components
overheat.

3.2.4 Limitations of MPI
As MPI is still an emerging imaging modality, the limitations associated with MPI have not been fully
flushed out. The primary limitation associated to MPI is the low spatial resolution. This makes the
delineation of signal from closely situated regions difficult. Often signal is summated, producing one
larger combined signal rather than smaller individual signals. Although this wasn’t a concern for this
project, future experiments may be impacted by this. While resolution is currently a major limitation, it
is expected that over time advances in MPI tracer technology will drastically improve the resolution of
MPI. An example of this progress can be seen in work done by the Conolly and Rinaldi labs who have
recently shown resolution improvements in the order of magnitudes with their superferromagnetic
chain tracers (35).
One of the main features of MPI is that only superparamagnetic iron is believed to produce signal. As
tissues are paramagnetic, background tissue does not produce a signal (1-8). This serves as both a
useful feature and a limitation. No anatomical reference is produced by MPI, making it difficult to
register signal to specific organs or tissues. The addition of separate scans from either MRI or CT are
required for co-registration of signal. Magnetic Insight has developed a dual MPI/CT system for this
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purpose, allowing both MPI signal and anatomical reference to be generated without moving the
mouse, or the introduction of time-delays. The MPI system used at Robarts does not have a CT
component and rather has a standard camera attached to it. Bright field photographs are taken which
can be overlayed on the MPI scan for reference.
As highlighted throughout this thesis, MPI is also subject to many of the limitations prominent in other
probe-based imaging modalities. Firstly, MPI cannot be used as a marker of cell proliferation. The
concentration of SPIO is diluted upon cell division and may be passed asymmetrically to daughter
cells. The dispersion of these cells results in a lower signal for your region of interest. Due to this
quantification of cells becomes imprecise at later time points, as the signal is not representative of the
number of cells in a region. Further, MPI cannot be used to indefinitely image dividing cell
populations (11-13,16,17), although Song et al., demonstrated that over a 20-day period, MPI signal
only decreased by approximately 20% (34). Additionally, when cells die, SPIO may be expelled from
the cell. This free SPIO will continue to produce a signal. Alternatively, this SPIO can be taken up by
bystander cells such as macrophages for hepatic clearance (16, 37) For these reasons, MPI cannot be
used as a measure of cell viability. These limitations prompted the additional use of BLI for cell
tracking in this thesis.

3.3 Challenges and Limitations of BLI
3.3.1. BLI light scattering
As BLI is dependent on the detection of light by a CCD camera, it is susceptible to unwanted light
scattering. One prominent example of this is light reflecting off the fur or skin of mice, resulting in
false signal. This is most pressing for mice with white fur, as white colours deflect light more readily.
The use of nude mice in this thesis minimizes this effect, although the skin itself will also scatter light
(38). During the in vivo experiments for this thesis, one of the 4 mice exhibited this on day 14. A false
signal was observed around the arm of the mouse, due to the positioning of the arm relative to the
camera. This can be seen in figure 3.1 below. This false signal can cause problems if it masks regions
of low cell numbers such as potential metastases.
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Figure 3.1 BLI light scattering observed on the arm of a mouse. One limitation of BLI is that skin
and fur will scatter light giving false signal. An example of this was observed in one of the mice during
the in vivo experiments described in chapter 2. The left arm has a signal due to the scattering of light off
the extended arm, making detection of secondary lesions difficult.
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3.3.2 Akaluc BLI background signal
In a Nature Methods paper published by Su et al., in 2020, they noted that Akalumine produced clear
background liver signal in mice, even in the absence of Akaluc. This finding was unique to Akalumine
and was not observed for other substrates (39). Nakayama et al., further demonstrated this
characteristic of Akalumine and hypothesized that Akalumine is metabolized by the liver to produce
micro-luminescence, a trait most often observed in hydrophobic molecules (40). Background signal
from the liver reduces the sensitivity of Akaluc BLI, especially when trying to detect signal from small
numbers of cells at or around the liver. No liver signal was observed in this experiment. Although
hepatic signal was not directly visible in this thesis, this could be a concern in future experiments.

3.3.3 BLI Signal Saturation
One limitation of BLI which was especially relevant during this thesis was signal saturation. Due to
extreme differences in cell numbers, the signal produced by the primary tumours in this experiment
were magnitudes greater than those from secondary lesions. While this high signal gives BLI a high
SNR, it also completely masks signal from any other location. Secondary signal sites were not visible
in BLI unless an opaque covering was placed on the mouse to shield the signal from the camera. This
shield blocked out the entire bottom half of the mouse, preventing the visualization of any region
proximal to the primary tumour. This may have resulted in potential sites of metastasis being
overlooked in BLI. An alternative solution to this problem would be to excise the primary tumour from
the mouse prior to imaging, however, this method is highly invasive.

3.3.4 Akalumine Cytotoxicity
Compared to most other BLI substrates, Akalumine-HCl has shown higher cytotoxicity. In 2017, Yeh
et al., demonstrated that at a concentration of 500 μM, cell viability of cells in the presence of
Akalumine decreased to 40%. At 1000 μM the viability was less than 20%. This was lower than any of
the other BLI reporters they tested (diphenylterazine, D-luciferin, Furizamine, and streptozotocin) (41).
In 2020, Nakayama et al., saw a rapid fall in heart rate, following the administration of Akalumine via
IP injection. It was found that Akalumine had a pH of 2.25, making it highly acidic. They hypothesized
that at concentrations greater than 10 mM this resulted in cardiac damage by acidosis. D-luciferin and
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the Akalumine derivate seMpai did not exhibit this (40). Additionally, in 2021, Amadeo et al., noticed
lesions at the site of subcutaneous injections, not observed with d-luciferin or IP injection. They also
hypothesized that this was due to the low pH (42).

3.3.5 Limitations of BLI
As mentioned before, no imaging modality is without its inherent limitations. Historically the biggest
limitation associated with BLI is signal attenuation (Sadikot et al., 2005; Kircher et al., 2011; Welsh &
Nouguchi, 2012; Yao et al., 2018; Close et al., 2011; Alsawaftah et al., 2021). Biological tissues
absorb light, which reduces the amount of signal which can reach the camera. Akaluc BLI significantly
minimizes this through its use of NIR light ((Kobayashi et al., 2010), although it is impossible to
completely remove this limitation. Signal from more deeply situated tissues will be more attenuated
than superficial tissues due to the volume of tissue that the light is interacting with. This gives BLI
limited three-dimensional spatial resolution (18,26-31).
Similar to PET, BLI is reliant on substrate availability and kinetics. In order to produce a signal, the
luciferin substrate must encounter the luciferase and be catalyzed to produce light. The interaction of
substrate and enzyme is random but is heavily influenced by the amount of substrate available to the
enzyme (26-29). This has a large impact on the amount of signal being produced. To reduce this effect,
Akalumine was administered in excess for this experiment. This, however, leads to the next limitation
of BLI: enzyme saturation. As the concentration of substrate increases, the luciferase enzyme will
eventually become saturated. Any increases in substrate concentration after this will have no impact on
the amount of signal produced. This sets the maximum signal that can be produced by any one cell. It
is important to note that the saturation point for Fluc (5.12 mM), is approximately 32-fold greater than
that of Akalumine-HCl (160 μM) which allows for the administration of more substrate. Amadeo et al.,
found that when substrates are administered subcutaneously (at saturation concentrations) this will
result in Fluc BLI having a higher signal than Akaluc BLI, although the same was not found following
intraperitoneal injection of substrates (42).

3.4 General Challenges and Limitations
3.4.1 Covid-19 Pandemic
To state the obvious, the COVID-19 pandemic has created its own set of challenges for everyone.
Following Western University protocols, our research lab at Robarts was shut down from mid-March
until June 2020. During this time, I was unable to conduct any experiments needed for the progression
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of this thesis. Both in vitro and in vivo experiments were affected by the shutdown. Ongoing cell
experiments were prematurely ended, requiring the thawing and recharacterization of a new cell batch
post lockdown. Additionally, the start of animal experiments was delayed as the Veterinary Services at
Robarts was understaffed, and a preference was given to ongoing experiments. This reduced the
number of cohorts which could be used in this experiment. Despite these problems, I completed as
many experiments as possible.

3.4.2 Limitations of Study
Limitations specific to the experiments conducted in this thesis are listed below:
1. The number of mice used in this experiment (n=4) should be increased to confirm any trends
observed in this data.
2. Mice were imaged on MPI and BLI on separate days, limiting the comparison that could be
made between the two modalities. This was done to minimize stress on mice, from prolonged
isoflurane anaesthesia exposure (20-40 min per scan).
3. Mice were imaged in the supine position for BLI, but the prone position for MPI. This change
makes direct comparison of signal locations difficult.
4. No ex vivo histology was done to confirm the presence of iron in MPI positive secondary
lesions, preventing us from confirming that these were metastases. By the time MPI and BLI
scans were aligned, tissues had already been collected and we were unaware that the signals
originated from different locations.
5. By day 14, the tumor burden on the mice became too large to continue the experiment. Mice
could not be imaged at later dates as originally planned.
6. Labelling cells with Synomag-D may result in extracellular iron. While cells were washed
thoroughly to avoid this, it is possible that trace amounts of iron remained which will lead to an
overestimation of iron content measure in MPI.
7. Iron content was not calculated using ICP-MS. When this experiment began, our lab did not
have access to ICP-MS to precisely measure the amount of iron in each cell. Numbers used in
this experiment were calculated from calibration lines, which may be less accurate.
Future work described in the following section could address some of these concerns.
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3.5 Future Work
3.5.1 Short Term Work
This research would benefit from additional mice. Due to time restraints associated with COVID-19,
only 4 mice were used in this study. The in vivo work described in this study should be repeated with
new cohorts of mice to reduce the impact of biological variance, and to draw conclusions about data
trends.
For the mouse experiments described in chapter 2, one million dual labelled cells were administered.
Later experiments should consider the use of fewer cells. This would serve 2 purposes. First, a lower
initial cell number would reduce the tumour burden, allowing for imaging over longer durations and a
more in-depth comparison of Akaluc BLI and MPI. Secondly, this may limit the camera saturation
observed in BLI at later time points. As the primary signal decreases, secondary lesions may become
more visible.
In the summer of 2020, the Foster lab was granted access to an advanced user interface for MPI by
Magnetic Insight Inc. This interface allows for fine-tuning of various imaging parameters to optimize
image acquisition. Our lab is working on testing out this new interface for future experiments. These
changes may increase the sensitivity and resolution of MPI for cell tracking experiments such as the
one outlined in this thesis.
This project would benefit from a faster pipeline of aligning BLI and MPI signals at endpoint. By
aligning the signals prior to tissue collection, we can ensure that secondary lesions positive for both
BLI and MPI can be examined ex vivo. This will allow for confirmation of metastases with both
modalities.
Since the start of this thesis, new tracers have become available which may improve sensitivity of both
MPI and BLI. For MPI we were able to detect as few as 8000 Synomag-D labelled cells in vitro (0.02
μg of iron; 2.18 ± 0.8 pg of iron/cell), however researchers have been able to detect as low as 250 cells
(7.5 ng of iron; 30 pg iron/cell) (34). If cells were labelled with higher concentrations of iron, fewer
cells would be detectable. Tracers such as the superferromagnetic chains developed by Conolly and
Rinaldi labs should be considered as they offer superior resolution and sensitivity, although these
tracers are currently cytotoxic (35). Recently an analogue of Akalumine has been developed known as
seMpai. SeMpai has almost the exact same emission spectra as Akalumine but has better solubility in
neutral solutions, which results in lower background hepatic signal. This could be useful in detecting
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metastases to the liver or in nearby regions such as the lungs. Additionally, seMpai has a pH of 7.91
making it less cytotoxic than Akalumine-HCl (40).

3.5.2 Long-Term Goals
In addition to the short-term work described in section 3.5.3, there are some long-term goals which
exceed the scope of this thesis. This was the first paper to apply Akaluc BLI and MPI for tracking of
any cell type. We chose to track breast cancer; however, this system could provide unique insight into
tracking of any cell type. MPI has been used in literature to track stem cells (43-47), pancreatic islets
(48,49), T cells (50), tumor associated macrophages (37), neural progenitor cells (33), dendritic cells
(36) and patient derived xenografts (51). It would be interesting to determine what benefits the addition
of Akaluc BLI could bring to tracking any of these cell lines. In addition to disease progression, this
system could also be used to visualize the efficacy of cell-based therapeutics. Specifically, the Ronald
lab is interested in tracking CAR-T and NK cells for immunotherapies. CAR-T cells have been tracked
with both MPI and Akaluc BLI independently (39,50).
Different routes of cell administration can result in cells localizing to different locations. This could
provide an avenue to test the ability of our Akaluc BLI MPI system for visualizing of cells in different
tissue types and organs. For example, intracardiac injection of cells results in approximately 15% of
cells arresting in the brain of mice (52). As the brain is one of the most difficult regions to image with
standard BLI, it would be interesting to see if this system provides any advantages for this particular
application.
We have demonstrated in this thesis, the advantages of combining Akaluc BLI, and MPI for cell
tracking, however, there are a plethora of other imaging modalities which could be used to
complement this multimodal system. A modality such as CT or MPI which provide anatomical
information would make localizing signal locations far easier. A CT/MPI system from Magnetic
Insight has recently become available, however our lab does not have access to such a system at this
time. Alternatively, MRI which can utilize the same SPIO tracers as MPI may make a simple
accompaniment for anatomical reference. MRI would also add a clinical probe-based imaging
component which is currently missing in this research. Further, PET could provide clinical reporter
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gene imaging for cell tracking. Each modality comes with its own set of advantages which could help
provide a more complete picture of cell fate.

3.6 Significance and Impact
Here we present for the first time the ability to track breast cancer cells with a dual Akaluc BLI and
MPI system. To date, no other cell type has been tracked using this multimodal approach. Akaluc BLI
offers a measurement of cell viability and proliferation which can be used in conjunction with the high
specificity, and direct quantification capabilities of MPI for long-term tracking of proliferative cell
populations. Both Akaluc BLI and MPI were able to detect cells from the primary tumor over the full
2-week study. Secondary lesions, corresponding to potential metastases were detected with both
modalities. What is interesting however, is that none of the sites visualized with Akaluc BLI were
visible with MPI and visa-versa. While a larger n size is needed to corroborate these results, this data
highlights an important example of why these two modalities should be used in conjunction. Use of a
single imaging modality may lead to missing important information, giving an incomplete picture of
cell fate. The research presented in this thesis lays the groundwork for multimodal Akaluc BLI and
MPI cell tracking of various cell types which would give valuable information on both disease
progression and the effect of potential therapeutics.
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